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ABSTRACT 
 A well-described set of biobehaviors and cognitive dysfunction emerge after stimulation 
of the immune system with pathogen-associated or danger-associated molecular patterns, and the 
endogenous cytokines elaborated in the immunologic response are key effectors (Dantzer et al., 
2008).  Just as an organism’s response to a pathogen is defined by the host immune system 
status, so too is the basal cytokine environment altered by the endogenous immune skew 
(Gordon and Martinez, 2010).  Shifting of cytokine skew has the capability to affect not only the 
immune and behavioral responses to exogenous stimuli, but to potentially alter biobehaviors 
observed in the naïve state (Moon et al., 2011). 
To test our hypothesis that skewing the immune system can alter biobehaviors exhibited 
in mice, we utilized two distinct models.  In Chapter 2, the project of endogenous immune skew, 
interleukin-4 (IL-4) knock-out (KO) mice were behaviorally phenotyped.  We have found that 
IL-4 KO animals display differences in burrowing, social exploration, elevated zero maze and 
the open field test, without any depressive-like behavior (forced swim test (FST), saccharin 
preference) or cognitive dysfunction (novel object recognition, novel object location, Morris 
water maze).  In Chapter 3, the second project utilized a novel exogenous stimulus, palmitic acid 
(PA).  We observed a dose-dependent decrease in home cage locomotion was noted two hours 
after PA treatment.  This locomotor deficit was not dependent on canonical proinflammatory 
signaling pathways (Toll-like receptor 4, Myeloid differentiation primary response gene 88, 
interleukin-1 receptor 1, interleukin-6, Tumor necrosis factor α) and was not PA specific.  After 
resolution of acute effects, PA treated animals displayed anxiety-like behavior (elevated zero 
maze, novel object investigation) but not depressive-like behavior (FST) or cognitive deficit (Y 
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maze).  Alterations to neurotransmitter balance in PA-treated mice were demonstrated in the 
amygdala and hippocampus. 
In conclusion, we demonstrated unique behavioral phenotypes in our endogenous 
immune skew and exogenous stimulus models.  While these two approaches differed in some 
parameter responses, both models resulted in anxiety-like biobehaviors in mice.  Taken together, 
these results suggest that a spectrum of effectors can lead to a common behavior.  Further 
investigation is warranted to determine if and when common pathways for the observed behavior 
emerge, which could potentially lead to novel pharmaceutical treatment targets for anxiety and 
related psychopathologies. 
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CHAPTER 1: LITERATURE REVIEW
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Summary 
 The macrophage (MΦ) is an essential cellular first responder in the innate immune 
system, sensing, alerting, removing and destroying intrinsic and extrinsic pathogens.  While 
congenital aplasia of granulocytes, T or B lymphocytes leads to serious disease, lack of MΦs is 
incompatible with life.  The MΦ, however, is not a monomorphic entity.  These constructers, 
repairers and defenders of the body are diverse in form and function.  What controls MΦ 
phenotype is beginning to be understood and involves a complex interplay of origination, 
location and microenvironment.  Common to all MΦ developmental pathways are pro-
inflammatory and anti-inflammatory cytokines.  MΦs respond to these bioactives in distinct 
ways developing recently recognized activation phenotypes that canonically support bacterial 
clearance (classical activation), parasite defense/tissue repair (alternative activation) and anti-
inflammation (de-activation).  Critically, the same cytokines which orchestrate immune defense 
and homeostasis dramatically impact sense of wellbeing and cognition by eliciting sickness 
symptoms.  Such behaviors are the manifestation of pro/anti-inflammatory cytokine action in the 
brain and are a direct consequence of MΦ function.  This review describes the “new” archetypal 
MΦ activation states, delineates microglia phenotypic plasticity and explores the importance of 
these macrophage activation states to sickness behavior. 
 
 
                                                          
1
 This section appeared in its entirety in Psychoneuroendocrinology and is referred to later in this 
dissertation as “Moon et al., 2011”.  Moon, M. L., McNeil, L. K., Freund, G. G. (2011). 
Macrophages make me sick: How macrophage activation states influence sickness behavior. 
Psychoneuroendocrinology. 36: 1431-1440. 
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Introduction 
Clinical manifestations of infection and inflammation have been recognized since 
antiquity — pain, swelling, redness, loss of function and fever that are known to be accompanied 
by behavioral manifestations — malaise, lethargy and anorexia.  These collective sickness 
behaviors are driven by cytokines, and are an integral part of the acute phase response initiated 
by innate immune effectors, especially phagocytic cells (Johnson, 2002; Kelley et al., 2003).  
Sickness behavior comprises an intrinsic motivational state responsive to infectious agents (Hart, 
1988; Dantzer et al., 2008). It is probable that as part of the acute phase response to infection, 
sickness behavior evolved as a mechanism for reducing pathogen load or minimizing pathogen 
damage (Read et al., 2008; Ra˚berg et al., 2009).  While these immune-associated biobehavioral 
manifestations (immunobehaviors) may confer a survival advantage to the host, those that linger 
unresolved after elimination of infection may be maladaptive and contribute adversely to 
conditions such as ageing, major depressive disorder and obesity. 
 
The immune system defends the body against pathogenic insults arising from both the 
external and internal environment. Immune responses are divided into innate and adaptive, with 
an intricate interchange between the two systems. While adaptive immunity utilizes somatic 
recombination and mutation to generate antigen-specific antibodies and T-cell receptors (TCRs), 
innate immunity relies on pattern recognition receptors (PRRs) encoded in the germline to 
recognize conserved motifs commonly displayed by pathogens or dangerously dysfunctional or 
transformed cells.  PRRs are somewhat promiscuous in comparison with the specificity of 
immunoglobulins and TCRs, but they are immediately available within and on the surface of 
cells, especially phagocytic dendritic cells, neutrophils and macrophages (MΦ) (Flannagan et al., 
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2009; Spits and Di Santo, 2011) that function in barrier maintenance and immune surveillance. 
These phagocytes are critical to both health and disease, ensuring recognition and removal of  
pathogens (Flannagan et al., 2009) and cellular debris (Mosser and  Edwards,  2008).  PRR 
ligand interactions stimulate the production of cytokines, which modulate function of both innate 
and adaptive immune cells.  It is cytokine-mediated communication within the neuroimmune 
system that is key to optimal immunological progression from innate to adaptive when pathogens 
challenge a host. 
 
While the host cytokine response to a pathogen challenge amplifies immunologic 
function and fosters immune system coordination, it also generates sickness behaviors (Dantzer 
and Kelley, 2007). As key cytokine producers, MΦs play a role in the balance of sickness and 
health through influencing immunobehaviors. Therefore, the degree and type of response 
displayed by MΦs has the potential to alter physical, emotive and cognitive function. Here we 
provide an overview of MΦs, MΦ activation states, and the interplay between MΦs and other 
immune cells. We also discuss MΦ cytokine profiles, the requirement of said cytokines for 
sickness behavior, future research and translational approaches to capitalize on MΦ plasticity. 
 
Background 
 Originating from hematopoietic-derived stem cell progenitors in the bone marrow, 
committed progenitor cells develop into separate subpopulations of granulocyte-MΦ precursors 
or MΦ/dendritic cell (DC) progenitors (MDPs) (Geissmann et al., 2010), which then differentiate 
into monocytes or common DC precursors. Monocytes emigrate from the bone marrow and 
circulate in the blood for 1—3 days.  Circulating monocytes may be attracted to an area of 
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inflammation by chemokines, then utilize surface molecules such as integrins to adhere and 
migrate into the tissue (Imhof and Aurrand-Lions, 2004), where interferon (IFN)-γ, interleukin 
(IL)-6 and macrophage colony-stimulating factor promote differentiation into MΦs (Delneste et 
al., 2003). A fraction of circulating monocytes are available to become resident, tissue-specific 
MΦs (Gordon and Taylor, 2005), such as those of the lung and liver.  Brain-resident MΦs, called 
microglia, are a unique subset of these resident cells.  Whereas other tissue-resident MΦs can be 
renewed by circulating monocytes, hematopoietic progenitors do not significantly add to the 
microglial population after birth (Ginhoux et al., 2010). Rather, myeloid progenitors are believed 
to establish the adult microglial population during early peri-natal development and proliferate 
locally, although the exact nature of this process is still unclear. 
 
Circulating monocytes and tissue MΦs survey the body and are the first cellular 
responders of the innate immune system, capable of a variety of actions that depend on the 
nature of the threat. Resident tissue MΦs can recognize and phagocytose invading organisms, 
encapsulating the invader in an intracellular vesicle known as a phagosome. Such engulfed 
materials elicit responses designed to neutralize the pathogen (Flannagan et al., 2009).  
Recognition of pathogen-associated molecular patterns (PAMPs) on the surface of the invaders, 
as well as endogenous danger-associated molecular patterns (DAMPs) produced in response to 
insults, is the role of extracellular and intracellular PRRs. The PAMPs that PRRs can identify are 
conserved microbial molecular patterns that seldom grossly mutate, allowing for generalized 
binding to a number of pathogens without prior exposure (Martinon et al.,2009). Signaling 
through these receptors triggers a number of bodily defense coordinators, including cytokines, 
chemokines, adhesion molecules and enzymes essential to host maintenance and  protection 
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(Rock and  Kono, 2008; Fukata et al., 2009).  MΦs also process phagosomal contents and 
present the resulting antigens on their surface thus activating cells of the adaptive immune 
system (Gordon, 2007).  Phagocytic capability of the MΦ is critical to both health and disease, 
ensuring recognition and removal of pathogens (Flannagan et al., 2009) and cellular debris 
(Mosser and Edwards, 2008).  MΦ cytokine production is also key to the pathogen response, 
impacting bodily processes both immune and non-immune, and it is this chemical 
communication that allows for coordination between disparate cells and distant sites. It has 
recently become clear that MΦs are not monochromatic in their effector response, but 
demonstrate a spectrum of novel activation profiles that alter the message they communicate. 
This concept of phenotypic alteration of immune cells was noted first in the Th cell where 
cytokines and other signals in the local environment interacted to drive Th subset differentiation 
defined by specialized cytokine profiles designed to execute specific immune tasks (Mosmann 
and Sad, 1996). Since this discovery, it is now increasingly evident that MΦs exhibit a similar 
responsiveness to signals received. Cytokines from multiple immunologic sources and other 
stimuli, including PAMPs on infectious and gut commensal microorganisms, synergize to alter 
the gene expression profiles of MΦs (Fig. 1.1), resulting in varied responses to immune 
activation (Gordon and Martinez, 2010). This gradient or ‘‘skewing’’ of phenotypes is clarifying 
how MΦs carry out their manifold functions within the innate immune system. It is still not 
clearly defined, however, how this MΦ skewing relates to immunobehaviors. 
 
Classical versus non-classical MΦ activation 
 Macrophages were recently shown to exhibit heterogeneous responses to stimulation, and 
classification of MΦ activation subsets somewhat parallels Th1 and Th2 polarization (Mills et 
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al., 2000).  The first distinctly defined pathway of MΦ activation was classical activation (M1) 
(Gordon and Martinez, 2010).  The M1 phenotype is co- induced from monocytes/resting 
macrophages by PAMPs and IFN-γ.  Natural killer (NK) cells produce a transient burst of IFN-γ 
that primes MΦs, and Th1 cells contribute additional IFN-γ responsible for phenotype 
maintenance (Mosser and Edwards, 2008).  M1 cells use arginine as a substrate for inducible 
nitric oxide synthase (iNOS, aka NOS2) resulting in high-output production of microbicidal 
nitric oxide (NO) (MacMicking et al., 1997).  In contrast to classical activation, the alternative 
activation (M2) pathway is, canonically, a response to parasitic infestation or tissue damage. The 
M2 phenotype is supported by IL-4 and IL-13 elaboration from Th2 cells, which promote a 
humoral response against extracellular pathogens. M2 cells use arginine as a substrate for 
arginase 1 (Arg1), degrading arginine to ornithine, which is a precursor for polyamines, proline, 
and collagen needed in wound healing (Gordon and Martinez, 2010). In addition to classification 
by cytokine- induced activation and arginine metabolism, M2 cells were also marked by high 
expression of the MΦ mannose receptor (MR) which is important for cell—cell recognition, 
serum glycoprotein turnover, and neutralization of pathogens through  recognition of complex  
carbohydrates on glycoproteins (Lee et al., 2002;  Colton,  2009). 
 
As immunologic characterization has progressed, a polarized dichotomy is no longer 
sufficient to describe all types of Th cells.  New T helper subsets have been identified, including 
Th17 and regulatory T cells (Treg) which are necessary to the elimination of extracellular 
pathogens and modulation of immune function, respectively. In addition, other possible T cell 
subtypes may exist such as Th3 and Th9 (Mosmann and Sad, 1996; Zhu et al., 2010), although 
the importance of these Th phenotypes has yet to be fully elucidated. Similarly, the functional 
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categorization of MΦs covers a complex landscape involving resident cells and elicited cells in 
homeostatic offense, immune defense, and disease-related dysfunctions. Recently, it has been 
recognized than many immune cells contribute to the wide range of MΦ activation states (Fig. 
1.1), including NK cells, neutrophils and other macrophages (Tsuda et al., 2004).  When Mills et 
al. proposed the M1—M2 dichotomy they recognized the definitions could represent ends of a 
continuum of MΦ activation phenotypes. Further study of the diversity of MΦ responses to 
activating stimuli have peppered that continuum with M1 and M2 subsets characterized by 
differences in activating cytokines, receptor expression, and chemokine response (Martinez et 
al., 2009). Most notable of these divisions is the deactivated MΦ (dMΦ). Previously considered 
M2 or an M2 variant, the dMΦ exhibits a unique phenotype (Table 1.1). This skew is induced in 
large part by TGF-β and IL-10 from Treg cells, a tolerogenic Th cell generated through exposure 
to parasites and harmless microorganisms as described by the hygiene hypothesis (Rook and 
Lowry, 2008; Rook et al., 2011).  Additional MΦ deactivating molecules exist and are produced 
from multiple sources immune and non-immune. These bioactives include glucocorticoids and 
prostaglandins (Fig. 1.1). dMΦs promote anti-inflammation including enhanced IL-10 and 
decreased IL-12 release (Mosser and Edwards, 2008). MΦs associated with cancer are often 
deactivated in the tumor microenvironment contributing to neoplastic growth (Jaiswal et al., 
2010). IL-10 released after immune stimulation may also aid in resolution of inflammation after 
immune challenge (Liu et al., 2006; Pils et al., 2010).   
 
 Non-classical activation phenotypes alter the responses of the MΦ to various stimuli 
when compared to M1. MΦs primed with IL-4, IFN-γ or IL-10 exhibit distinct basal gene 
profiles. Treatment of M1s with lipopolysaccharide (LPS, also known as endotoxin), an 
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immunogenic component of Gram-negative bacteria cell walls, induces secretion of tumor 
necrosis factor (TNF)-α and IL-1β. Upon LPS stimulation, dMΦs produce less TNF-α and IL-1β 
(Dagvadorj et al., 2008; Schaljo et al., 2009; Chusid et al., 2010) and  IL-1β signaling is 
decreased (Strle et al., 2008).  While M2s treated with LPS still produce pro-inflammatory 
cytokines with similar time kinetics to M1s, the quantity released is lower (El Chartouni and 
Rehli, 2010; Gratchev et al., 2006).  However, this phenotype of reduced inflammatory mediator 
production can be reversed.  Changing the cytokine environment alters established MF 
phenotypes (Stout et al., 2005) suggesting that an immediate response to an inflammatory 
stimulus may be drift to non-classical MΦ phenotypes relative to M1. Additionally, a prolonged 
exposure to a new cytokine milieu can further skew or re-skew the MΦ activation profile. 
 
While much of the work involving MΦ activation is focused on the periphery, microglia, 
the resident MΦs of the central nervous system (CNS), also exhibit a number of activation states. 
As with peripheral MΦs, microglia respond to the prevailing cytokine milieu and display 
markers of M1, M2 or deactivation (Colton, 2009). This is important because microglia complete 
immune-to-brain communication by releasing a variety of pro-inflammatory bioactives in 
response to pro-inflammatory peripheral signals (Dantzer et al., 2008). Thus, MΦ activation 
states of both the peripheral and neuroimmune systems should drastically alter the behavioral 
response to inflammation. 
 
Microglia activation can be skewed in a manner similar to that of peripheral MΦs, and 
microglial phenotypic skew may potentially influence central response to an immune challenge. 
Microglia and peripheral MΦs treated with IL-4 and IL-13 display similar gene profiles (Colton 
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et al., 2006), indicating that Th2 cytokines can drive microglial alternative activation. Similar to 
peripheral MΦs, pretreatment of microglia in culture with IL-4 mitigates the induction of TNF-α 
and iNOS after LPS stimulation (Kitamura et al., 2000). Resident microglia also express the M2 
markers Ym1 and Arg1, and lack NO production in an IL-4 dependent manner (Ponomarev et 
al., 2007). In addition to its direct action on microglia, IL-4 increases expression on neurons of 
CD200, a membrane glycoprotein that inhibits glial activation (Lyons et al., 2007).  The 
exogenous signals affecting microglia, however, are much different than those of MΦs.  
Protected by the blood-brain barrier, microglia are not directly exposed to circulating bioactives 
such as cytokines or PAMPs. Instead, crosstalk between the CNS and peripheral signals occurs 
in several areas, most notably the subarachnoid space, ventricle walls and choroid plexus 
(Derecki et al., 2010), and signals from the periphery can induce endogenous CNS mediators by 
signaling through endothelial cells or reverse neurotransmission via the vagus nerve (Dantzer et 
al., 2008). Endogenous microglial inflammatory stimuli include neurotransmitter alterations (i.e. 
glutamate) and ATP.  Microglia also respond to loss of neural input becoming repressed in 
function through tonic stimulation of CX3CR1 (Ransohoff and Perry, 2009). Despite the 
differences between inflammatory activators of MΦs and microglia, distinct activation states 
remain a consistent theme in the cellular responses. 
 
Classical MΦs and sickness behavior 
 Animals and people display a set of immune driven manifestations collectively known as 
‘‘sickness behavior’’ in response to pathogenic infection. In animals these immunobehaviors 
include anorexia, anhedonia, decreased locomotion, truncated social exploratory behavior, 
reduced grooming, diminished burrowing and loss of cognitive ability, all of which can be 
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induced experimentally by injection of LPS and/or pro-inflammatory cytokines (Dantzer et al., 
1998).  For many years sickness behaviors were considered maladaptive, but a review by Hart 
re-imagined these behaviors suggesting that they evolved to cope with disease (Hart, 1988).  Hart 
proposed that increased sleep combined with reduced grooming, feeding and locomotion 
conserved energy needed to combat infection. Piloerection helped maintain increased body 
temperature for inhibiting pathogen growth.  These ideas were expanded upon, and a detailed 
review of sickness behavior (Dantzer and Kelley, 2007) summarizes the history of sickness 
research beginning in the mid-1950s to current theories, with some work emphasizing sickness 
behavior as a non-specific response, an expression of a motivational state or as part of a pain 
defense system. 
 
While the evolutionary development of sickness behavior is likely to remain in debate, 
the mechanisms behind these immunobehaviors have drawn increased interest.  Initially, the 
observation that pro-inflammatory cytokines increased after infection or LPS administration 
sparked the idea that these bioactives were responsible for the sickness symptoms seen. IL-1β 
and TNF-α are among such cytokines up-regulated in the brain (Gatti and Bartfai, 1993) and 
periphery (Zuckerman et al., 1989).  Peripheral or central administration of IL-1β and/or TNF-α 
induce immunobehaviors that mimic those seen in infection or endotoxin administration 
(Dantzer et al., 1998). How these peripheral signals communicate with the brain to produce 
behavioral change is still unresolved, although several redundant mechanisms have been 
proposed. These mechanisms include: (1) cytokine stimulation of afferent nerves (e.g. vagal);   
(2) cytokine access to the brain at the circumventricular organs (CVO) due to lack of a robust 
blood-brain barrier; (3) cytokine transport to the brain from the blood via cytokine transporters; 
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and (4) cytokine stimulation of brain prostaglandins by brain-based endothelial cells and 
perivascular MΦs (Dantzer et al., 2008).  One of these pathways may be principally responsible 
for the central response to a peripheral infection or they may all work in concert. Regardless of 
the specific mechanism, MΦs play an important role in mediating the sickness response due to 
their ability to recognize microbial components and produce pro-inflammatory cytokines that 
invariably trigger the innate immune system in the brain. 
 
Non-classical MΦs and sickness behavior 
 Since pro-inflammatory cytokine elaboration by M1s induce immunobehaviors, it would 
seem likely that bioactives released by M2s or dMΦs could potentially modify sickness 
behavior. Exogenous IL-10 given centrally abrogates both CNS and peripheral LPS-induced loss 
of locomotor activity and social exploration (Nava et al., 1997; Bluthe´ et al., 1999). The 
researchers hypothesized that this effect was in part due to the ability of IL-10 to deactivate MΦs 
and inhibit the activity and production of pro-inflammatory cytokines. Indeed, IL-10 knock out  
(KO) mice challenged peripherally with LPS exhibit a prolonged and exaggerated 
proinflammatory cytokine induction in plasma and brain when compared to wild-type controls 
(Krzyszton et al., 2008; Richwine et al., 2009), and this increased inflammatory state is 
associated with deficits of cognitive and motor function. 
 
As with dMΦs, there is a paucity of research specifically investigating behavioral effects 
of M2 activation. Currently, MΦ phenotype research focuses on immunological response over 
biobehavioral change. A review of the literature finds few studies directly concerned with 
alterations in behavioral responses due to MΦ skew. Based on previous studies demonstrating a 
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link between adaptive immunity and cognition, Derecki et al. (2010) investigated the mechanism 
for this phenomenon finding it regulated by T cell-derived IL-4. Through the use of T cell 
deficient mice and adoptive immune cell transfer, they determined that IL-4-producing Th cells 
are recruited to the subarachnoid spaces, ventricle walls, and choroid plexus after a cognitive 
training task.  This aforementioned T cell response was shown to promote brain-derived 
neurotrophic factor (BDNF) production by astrocytes as well as regulate the inflammatory 
phenotype of meningeal myeloid cells.  Interestingly, these studies demonstrated that M2s appear 
to act in a T cell-independent manner to improve cognitive function in T cell deficient mice 
(Derecki et al., 2011). 
 
In addition to the work by Derecki et al., we have investigated diet-induced immune 
alterations in endotoxin mediated sickness.  This research showed that feeding mice a diet 
supplemented with the soluble fiber pectin protects mice from LPS-induced sickness behavior 
(Sherry et al., 2010).  The pectin fed mice displayed basal up-regulation of IL-1 receptor 
antagonist (IL-1ra) and IL-4, a Th2 skew, and peritoneal MΦs expressing M2 markers that, when 
stimulated ex vivo with LPS, demonstrated dampened pro-inflammatory cytokine production. 
When the soluble fiber diet was fed to IL-4 KO mice, the effect of pectin on Th cell skew and 
sickness behavior was reduced, suggesting that IL-4 was key. 
 
 While the Derecki et al. and Sherry et al. studies may be unique in their aims to directly 
investigate the impact of M2 activation on behavior, they are not alone in revealing a MΦ 
activation state effect on immune-mediated sickness.  Other researchers have essentially studied 
the skewing mechanism without measuring standard MΦ activation state markers. One such area 
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of investigation has examined the roles of IL-4 and IL-13 through exogenous administration of 
these bioactives as well as exploring their function in KO mice. IL-4 KO mice administered 
intraperitoneal LPS showed a greater reduction in exploratory behavior than wild-type controls, 
and this was associated with attenuated proinflammatory cytokine production by glia (Lyons et 
al., 2009).  Intracerebroventricular administration of IL-4 12 h prior to intraperitoneal LPS 
diminished the endotoxin-induced decrease in social exploration in rats (Bluthe´ et al., 2002). 
However, intracerebroventricular administration of IL-13 prior to intraperitoneal LPS had no 
effect. When LPS was administered concurrently with IL-13, behavioral changes potentiated 
(Bluthe´ et al., 2001).  The above findings raise the possibility that IL-13 is not as effective as 
IL-4 in inducing the M2 phenotype. Additionally, the work by Bluthe´ et al. found that co-
administration of intracerebroventricular IL-4 or IL-13 with intraperitoneal LPS served  to  
enhance LPS-induced sickness behavior, and research from a different group found that 
intracerebroventricular IL-4 during high fat diet feeding increased hypothalamic pro-
inflammatory cytokine gene expression (Oh-I et al., 2010).  These results indicate that whereas a 
pre-existing cytokine-induced M2 phenotype may reduce the classical response, IL-4 or IL-13 
may serve to enhance the inflammatory functions of MΦs when provided concurrently with an 
immune stimulus. 
 
Another wide-ranging line of research involving immuno-behaviors concerns those 
elicited by IL-1. While not directly examining M1 versus M2 skew in sickness, extensive work 
has been performed detailing MΦ generated IL-1. The IL-1 system is very important to 
immunobehaviors. Similar to LPS, IL-1β reduces rodent activity in an open field and decreases 
24 h food intake and body weight (Wieczorek et al., 2005).  In opposition to IL-1β and the 
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lesser-studied IL-1α, is the endogenous IL-1 receptor antagonist, IL-1ra, and the decoy receptor 
IL-1r2.  These bioactives modulate the IL-1 system and appear to be critical to inflammation 
down-regulation and/or resolution. Treatment of human monocytes with IL-13 enhanced IL-1r2 
and IL-1ra expression and decreased the activity of caspase-1, the enzyme responsible for 
production of mature IL-1β (Scotton et al., 2005).  Studies in diabetic mouse models, which 
exhibit IL-4 resistance, showed that such mice fail to appropriately up-regulate IL-1ra and IL-1r2 
in response to immune challenge (O’Connor et al., 2005). Therefore, M2s may not only reduce 
their production of IL-1β but also increase production of IL-1 antagonists. 
 
Peripheral IL-1ra is effective at blocking the decrease in social and food motivated 
behavior after peripheral IL-1β administration. Furthermore, centrally administered IL-1ra has 
been repeatedly shown to block the decrease in social exploration induced by both central and 
peripherally injected IL-1β (Kent et al., 1992; Bluthe´ et al., 1995, 1997).  Neutralizing 
peripherally administered IL-1β appears sufficient to ablate certain sickness behaviors. 
Furthermore, IL-1 signaling in the brain appears essential for IL-1β-induced immunobehaviors, 
as centrally administered IL-1ra inhibits the effects of both intraperitoneal and 
intracerebroventricular delivered IL-1β.  Decrease in sweetened milk intake after LPS or 
influenza infection is attenuated by intraperitoneal IL-1ra (Swiergiel et al., 1997), and peripheral 
LPS-induced depression in food intake is partially reversed. Up-regulation of pro-inflammatory 
cytokine expression in the hypothalamus is blocked by intracerebroventricular IL-1ra (Laye´ et 
al., 2000), suggesting that IL-1 is important to but not solely responsible for LPS- and infection-
related sickness behavior.  Obesity induced by a high fat diet (HFD) augments serum IL-1ra, and 
obese mice recover (after a hypoxia challenge) social exploratory activity five times faster than 
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mice fed a normal low fat diet (LFD) (Sherry et al., 2009). This effect of a HFD was attenuated 
by neutralization of IL-1ra with administration of an anti-IL-1ra antibody. Interestingly, the 
source of this endogenous IL-1ra is visceral fat MΦs but the activation state of these fat-based 
MΦs is still unclear (Lumeng et al., 2007; Zeyda et al., 2007). In fat from HFD-fed mice, M2 
markers are substantially increased as is the ‘‘dendritic cell marker’’ CD11c leading some to 
term these MΦs ‘‘non-inflammatory M1-like MΦs’’ (Li et al., 2010; Shaul et al., 2010). These 
unique fat-based MΦs appear tied to insulin resistance and may be the source of IL-1ra in HFD-
fed mice. 
 
Exogenous cytokine administration has shed some light on MΦ skew in sickness 
behavior. However, further investigation of specific MΦ phenotypes is necessary, and an animal 
model with natural MΦ skewing would be valuable to understanding the role of MΦ activation 
states in immunobehaviors. Different strains of mice show disparate responses to immune 
stimuli, and an important strain comparison for this review is between C57BL/6 and Balb/c mice.  
Treatment of lymphocytes isolated from spleen with the mitogen Concanavalin A elicits cytokine 
production. Stimulated splenocytes from C57BL/6 mice secrete high IFN-γ and low IL-4 
indicating a Th1 skew, whereas an opposite cytokine ratio is observed in splenocytes from 
Balb/c mice (Mills et al., 2000).  As mentioned earlier, cytokines produced by Th cells influence 
the activation of MΦs, so it would be expected that the MΦ populations of C57BL/6 and Balb/c 
mice would exhibit different skews. Mills et al. has shown that in response to ex vivo stimulation 
with IFN-γ or LPS, C57BL/6 MΦs demonstrate an increase in iNOS and decrease in arginase 
activity, while Balb/c MΦs show only an increase in arginase.  A comparison of C57BL/6 and 
Balb/c mice could, therefore, be an important bridge between MΦ activation state and 
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immunobehaviors.  Unfortunately, research comparing the behavior of these two mice strains has 
been limited, largely confined to anxiety, stress and memory. Cognitive deficit induced by stress 
was seen in Balb/c but not in C57BL/6 mice (Palumbo et al., 2010), and Balb/c mice showed 
higher home cage but lower open field activity (Tang et al., 2002).  These results suggest basal 
and stimulated behavioral differences between mice strains, thus, use of naturally skewed mice 
could add significantly to the knowledge base regarding MΦ-mediated behavioral responses. 
 
Another mouse model with potentially disparate MΦ activation states is that of young 
versus aged mice.  Aged mice exhibit an increase in pro-inflammatory cytokine production and 
glial reactivity markers in the basal state (Sparkman and Johnson, 2008). Additionally, microglia 
in aged animals show the primed response (Godbout  et al., 2005) characterized by exaggerated 
cytokine elaboration to innate immune challenge similar to what is observed in mouse models of 
chronic neurodegeneration (Combrinck et al., 2002; Cunningham et al., 2005).   Aged animals   
challenged with LPS display prolonged sickness, higher cytokine induction and more severe 
cognitive deficits when compared to young animals (Godbout et al., 2008; Huang et al., 2008; 
Wynne et al., 2010). Depressive-like symptoms are also exacerbated in LPS treated aged mice 
compared to young mice evidenced by increased immobility in the forced swim and tail 
suspension tests (Godbout et al., 2008). Down-regulation of IL-1 signaling, either through  IL-
1ra administration or dietary resveratrol, an antioxidant that reduces LPS-generated IL-1, 
partially resolves the enhanced sickness behaviors seen in aged animals (Abraham and Johnson, 
2009a,b). Aged mice also exhibit a longer diminution in locomotor activity compared to young 
mice in response to exogenous IL-1β (Sparkman and Johnson, 2008). Therefore, given a basal 
pro-inflammatory cytokine skew, enhanced microglial sensitivity to LPS and up-regulation in the 
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IL-1 signaling system, aged mice appear skewed M1. Whether this is due to loss of M2s/ dMΦs 
or due to a unique aged MΦ phenotype is not yet known but further research regarding MΦ 
phenotypes in ageing is important due to the increased incidence of neuroinflammation-
associated disorders seen in elderly and diabese human populations. 
 
Concluding remarks 
 MΦs appear critical to sickness behavior as evidenced by MΦ depletion studies causing 
an ablation of several LPS-induced immunobehaviors (Groeneveld et al., 1988), but MΦs as the 
sole cause of sickness behavior has yet to be proved definitively. While it is known that MΦ 
stimulation elicits cytokines and that these cytokines induce immunobehaviors, the connection 
between MΦs and sickness requires further study.  Important questions still to be answered are 
whether MΦ-derived cytokines are exclusively responsible for immunobehaviors and what the  
roles are of various cytokines and cytokine sources in initiation, propagation, and termination of 
sickness.  Through the use of radiation depletion, it was demonstrated that TLR4 on non-
hematopoietic cells is essential for endotoxin-induced CNS inflammation, and this response is 
independent of systemic cytokines (Chakravarty and Herkenham, 2005). While this study 
showed a role for non-blood borne TLR4 in CNS inflammation, the specific cells in the CNS 
critical to actuating immunobehaviors remains unclear. Experiments critical to future research in 
sickness would benefit from the development of tools to knock-out MΦs, MΦ PRRs and MΦ 
cytokine production in an inducible and tissue/cell-specific manner. 
 
In addition to examining the importance of MΦs and their skew to sickness behavior, 
further investigation is needed to unlock the secrets of human MΦs and translate activation states 
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observed in animal models to the clinical setting. Some markers of MΦ activation, such as nitric 
oxide production, may not be as important in humans as it is in mice.  However, should it be 
found that human MΦ phenotypes reflect those observed in animal models, this would be very 
important to human health.  Classic sickness behavior, dysregulated inflammation and cytokines 
are associated with depression in humans (Dantzer et al., 2008).  Nearly 45% of malignant 
melanoma patients receiving interferon-α experience major depression (Musselman et al., 2001). 
Rates of depression are also higher in patients suffering from chronic inflammatory disorders, 
such as Alzheimer’s disease (Colton et al., 2006). Since MΦs and their precursors are relatively 
easy to isolate and culture from the human body (Davies and Gordon, 2004), these cells make 
therapeutic ex vivo bioengineering possible, where MΦs can be manipulated outside the body 
and then returned to the patient (Leor et al., 2006). 
 
Whether sickness behavior is an adaptive trait that isolates the ill from the non-ill to curb 
the spread of infectious disease or is part of a reparative/regenerative process that is necessary to 
efficiently combat illness is open to debate.  What is not in dispute is that cytokines such as those 
derived by MΦs are required for immunobehaviors. MΦs integrate a vast array of dynamic 
microenvironmental signals then adapt to coordinate the immunologic response to a changed 
physiologic state or microbial invasion.  Given the different milieus in which MΦs reside, their 
phenotypes likely span an enormous spectrum controlled by things as pedestrian as pH and as 
exotic as strategic metals.  To deconstruct this complexity it is reasonable to understand MΦ 
activation states as a trinity of archetypal phenotypes (M1, M2, and deactivated). However, this 
simplified scheme cannot predict why influenza can cause mild flu-like symptoms in some and 
potentially fatal cytokine storm in others.  Neither can it answer other key questions including:  
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Do macrophage phenotypes impact mood or behavior?  Or is the macrophage altering condition 
of the overweight/obese state manifest as a biobehavioral sickness.  Thus, more research is 
needed to understand how and why macrophages make me sick and if these phenotypes can be 
manipulated in a therapeutic fashion to make me feel better. 
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CHAPTER 2: IL-4 KO MICE DISPLAY ANXIETY-LIKE BEHAVIOR WITHOUT 
COGNITIVE DEFICIT
2
 
 
Abstract 
 Endogenous immune skew has the potential to impact biobehaviors by altering naïve 
cytokine concentrations.  As previous research has demonstrated cognitive deficits in interleukin 
(IL)-4 deficient mice, we sought to determine the complete biobehavioral phenotype in these 
animals.  IL-4 knock-out (KO) animals were compared to wild-type (WT) C57BL/6 control mice 
in a behavior phenotype battery.  Burrowing and social exploration were assessed to determine 
general behavior differences, depressive-like behavior was tested using the forced swim test 
(FST) and saccharin preference, the Morris water maze (MWM), novel object (NO) and novel 
location (NL) tests were performed for cognitive function, and the elevated zero maze (EZM) 
and open field test (OFT) were used to probe anxiety-like behavior.  IL-4 KO mice showed 
altered generalized behaviors, with decreased burrowing and increased social exploration.  No 
differences were seen in depressive-like behaviors or cognitive function between KOs and WT 
animals as assessed by FST, saccharin preference, MWM, NO and NL.  In the EZM, IL-4 KO 
mice spent less time in the open arm, whereas KO animals spend more time in the center of the 
OFT without a difference in total locomotion versus WT controls.  In conclusion, IL-4 KO mice 
display a unique biobehavioral phenotype when compared to WT controls, characterized by 
paradigm-dependent anxiety-like behavior, without differences in depressive-like behavior or 
                                                          
2
 This chapter is in preparation for submission. Moon, M. L., Joesting, J. J., Blevins, N. A., 
Lawson, M. A., Gainey, S. J., McNeil, L. K., Freund, G. G. (In Preparation). IL-4 KO Mice 
Display Anxiety-like Behavior Without Cognitive Deficit. 
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cognition.  These data suggest that endogenous immune skew impacts unstimulated biobehaviors 
in mice. 
 
Introduction 
 The interaction between the peripheral immune system and central nervous system (CNS) 
is a relatively young area of rapidly expanding focus (Dantzer and Kelley, 2007; Kelley and 
McCusker, 2014), with links found between inflammation and neurological and psychiatric 
diseases (Debnath and Venkatasubramanian, 2013; Haroon et al., 2012; Hou and Baldwin, 2012; 
Irwin and Rothermundt, ; Slavich and Irwin, 2014).  Cytokines are thought to be a mechanism of 
this crosstalk (Dantzer et al., 2008) by altering neuronal functioning directly and indirectly 
(Felger and Lotrich, 2013; Yirmiya and Goshen, 2011)   Specific cytokines have been implicated 
in biobehavioral complications, most notably the proinflammatory interleukin (IL)-1β and tumor 
necrosis factor (TNF)-α (Gosselin and Rivest, 2007; McAfoose and Baune, 2009; Wang and 
Shuaib, 2002).  While the role of proinflammatory cytokines in biobehavioral alterations has 
been thoroughly studied, less is known about anti-inflammatory cytokines in immune-mediated 
behaviors. 
 
 Cytokines such as IL-4 and IL-10 play a critical role in balancing responses of the 
immune system.  Whereas IL-1β and TNFα promote immune activation and proinflammation 
(Opal and DePalo, 2000), IL-4 and IL-10 are involved in alternative immune responses and 
resolution of inflammatory events (Dinarello, 2000).  In animal models using lipopolysaccharide 
to stimulate a proinflammatory response with subsequent cytokine-induced behavior changes, 
administration of exogenous IL-10 or IL-4 have been shown to mitigate the biobehavioral effect 
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of the stimulus (Bluthé et al., 1999; Bluthé et al., 2002).  As the overall balance of immune 
function and responsiveness is mediated by the endogenous cytokine environment of the 
organism (Mosser amd Edwards, 2008), a dysfunction in anti-inflammatory cytokine production 
likely influences naïve biobehaviors similar to their proinflammatory relatives (Moon et al., 
2011).  Indeed, mice lacking IL-10 display depressive-like and anxiety-like behavior (Mesquita 
et al., 2008), while IL-4 knock-out (KO) animals reportedly demonstrate cognitive dysfunction 
(Derecki et al., 2010). 
 
 In this study, we expanded upon previous research in IL-4 KO mice.  While animals 
lacking IL-4 have been found to be cognitively impaired, and could be rescued by adoptive 
transfer of wild-type (WT) T cells (Derecki et al., 2010) or alternatively activated macrophages 
(Derecki et al., 2011), the full behavioral profile in this strain has not yet been defined.  Recent 
studies in IL-1 receptor KO mice have shown the benefit of complete behavioral phenotyping, as 
one study found these animals to have hippocampal memory deficits (Avital et al., 2003) while 
the other demonstrated hyperactivity and decreased anxiety, but without impaired hippocampal-
dependent memory (Murray et al., 2013).  As behavior testing can be confounded by a number of 
factors (York et al., 2012), we sought to determine the whole biobehavioral picture of IL-4 KO 
mice. 
 
Methods 
Materials- All reagents were purchased from Sigma-Aldrich (St Louis, MO). 
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 Animals- Animal use was performed according to protocols approved by the Institutional 
Animal Care and Use Committee at the University of Illinois. Wild-type C57BL/6J (WT) and 
interleukin (IL)-4 knock out (KO) mice (on a C57BL background) were originally purchased 
from The Jackson Laboratory (Bar Harbor, ME) and bred in-house.  Mice were provided food 
and water ad libitum in standard shoebox cages.  Animals were group housed (up to 8 per cage), 
then moved to individual housing the day prior to testing unless noted otherwise. Housing 
temperature (72 °F) and humidity (45–55%) were controlled, and a 12/12h reversed dark-light 
cycle (2100–0900 h) was maintained. Animal behavior was video recorded using a Sony HDR-
XR500V Night Shot capable video camera (Tokyo, Japan). Mice used were between 8 and 20 
weeks of age. All behavior testing was completed under red lights in the dark cycle unless 
otherwise indicated.  A total of 146 mice were used. 
 
 Burrowing- As previously described (Kaczmarczyk et al., 2013), mice were individually 
housed overnight in the presence of a burrow (20 cm long polyvinyl chloride (PVC) piping 
capped at one and raised 1.3 cm at the open end). Testing was initiated by filling the burrow with 
approximately 200 g of food pellets. Food was only available from the burrow, but water was 
provided ad libitum. Mice were allowed to interact with the filled burrow for 10 h, at which point 
burrowing amount was determined from combined weight of burrow and food before and after 
testing. 
 
Social Exploration- Social exploratory behavior was performed as we have described 
(Sherry et al., 2010). Briefly, a novel male 3- to 4-week-old conspecific mouse (challenge 
mouse) was confined to a 7.62 × 7.62 cm wire mesh enclosure placed in the home cage of the 
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test mouse. The test mouse was exposed to the challenge mouse and video recorded for 5 min. 
Investigation time (nose contact) of the challenge mouse by the test mouse was quantified by a 
blinded observer.  
 
Forced swim test- A clean white cylindrical PVC container (diameter 16 cm; height 31 
cm) was filled with 20 cm of water maintained at 25 ± 1 °C for each mouse. Mice were moved 
from their home cage to the test container and video recorded for 5 min.  Immobility was 
evaluated from the video as we have described (Park et al., 2011).  
 
Saccharin Preference- Saccharin preference testing was performed as previously 
described (Lavin et al., 2011).  Briefly, mice were singly housed in standard cages with two 
bottles of water three days prior to testing for acclimation. Testing was started at the beginning 
of the dark cycle by replacing one of the waters (randomized to right verses left) with a 0.4% 
sodium saccharin solution (Sigma-Aldrich). Bottles were weighed before and after 24 h of access 
and total consumption calculated.  Results presented as % saccharin preference (saccharin 
volume divided by total fluid volume consumed). 
 
Morris Water Maze- Mice were tested as previously described (Sparkman et al., 2006).  
Briefly, in a 100 cm diameter by 30 cm deep circular tank filled with water (21-23°C), a 10 cm 
diameter transparent round platform was placed 0.5-1cm below the water surface. Animals were 
trained for 4 days (acquisition phase) at three trials per day.  Mice were placed in one of three 
quadrants other than the one containing the hidden platform and allowed to swim for 60 s or until 
reaching the platform.  If mice failed to locate the platform, they were placed on the platform for 
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30 s.  After three consecutive trials mice were returned to their home cage and placed under a 
heat lamp for 10 min.  On day 5 the platform was removed and each mouse was tested (probe 
trial) for 60 s.  On day 6 the platform was placed in the quadrant opposite the original learned 
quadrant (reversal training) and mice were trained for three trials.  On day 7 mice were tested 
(reversal test).  All phases of training and testing were video recorded by a camera mounted 
above the maze and analyzed using Noldus Information Technology EthoVision XT 7.  All 
testing was performed during the dark phase, with spatial clues illuminated by dim white light. 
 
Novel Location Recognition- Mice were individually housed in a large rat-sized cage (26 
cm x 48 cm x 21 cm) with a spatial cue marked on one side.  During the training phase, two 
identical objects were presented to the animal on one side of the cage.  After overnight training, 
the objects were removed from the testing arena and sanitized with ethanol.  Testing was 
initiated after 1 hr.  During testing, one of the objects was replaced in the same location as during 
training (familiar location).  The second object was placed on the opposite end of the arena 
(novel location).  Investigation was video recorded for 5 min and evaluated by a blinded 
observer. Novel and familiar location % investigation was calculated by dividing the time spent 
examining each location by the total investigation time. 
 
Novel Object Recognition- Novel object recognition was examined as previously 
described (Chiu et al., 2012; York et al., 2012).  Mice were individually housed overnight in a rat 
cage-sized arena (26 cm × 48 cm × 21 cm) containing two identical objects (training). After 
overnight training, objects were removed and cleaned and sanitized with ethanol.  Testing was 
initiated after 1 h.  During testing, two objects were replaced in the cage, one seen during 
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training (familiar object) and one unfamiliar object (novel object).  Object investigation was 
video recorded for 5 min and evaluated by a blinded observer. Novel and familiar object % 
investigation was calculated by dividing the time spent examining each object by the total object 
investigation time. 
 
Zero maze- As previously described (Kaczmarczyk et al., 2013), a zero maze, with 4 
quadrants, 2 of which had high walls (14 cm), was under white light illumination. Mice were 
placed in the high wall section to begin testing and video recorded for 5 min. Time spent in the 
non-high wall area (open arm) was quantified by a blinded observer.  
 
Open Field Test- As we have described (York et al., 2012), mice were placed in a novel 
open field arena (66 cm length x 45.7 cm width x 22.9 cm height) with lighting positioned to 
generate a 9 cm shadow from each side wall. Mice were allowed to explore the novel arena and 
video recorded for 5 min. Noldus Information Technology EthoVision XT 7 was used to track 
the mouse, determining mouse center point movement and time spent in the shadowed and non-
shadowed areas of the arena. Results are presented as raw time (s) and distance moved (cm). 
 
Statistics- Data are expressed as mean ± SEM. Analysis was conducted using Sigma Plot 
11.2 (Systat Software, Chicago, IL). One-way ANOVA was run for all experiments except 
Morris Water Maze, which required two-way repeated measures ANOVA for Task Acquisition. 
Post-hoc comparison used Tukey’s test. Statistical significance was determined as p<0.05. 
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Results 
 IL-4 KO mice display burrowing and social exploration differences- Figs. 2.1A and 2.1B 
show IL-4 KO mice display decreased food pellet burrowing (WT vs IL-4 KO, 156.0 ± 18.0 vs 
79.8 ± 23.2, p=0.017) and increased social exploration of a novel juvenile (WT vs IL-4 KO, 
130.0 ± 5.0 vs 148.4 ± 6.9, p=0.039) when compared to WT mice. 
 
 IL-4 KO mice do not exhibit depressive-like behavior- Fig. 2.2A shows that WT and IL-4 
KO mice do not differ in immobility in the forced swim test (WT vs IL-4 KO, 127.0 ± 6.0 vs 
121.0 ± 9.3, p=0.580).  Fig. 2.2B demonstrates WT and IL-4 KO mice have the same preference 
for a saccharin-sweetened solution over water (WT vs IL-4 KO, 93.7 ± 0.5 vs 92.9 ± 0.8, 
p=0.398).   
 
Spatial and non-spatial memory is not impaired in IL-4 KO mice- During the acquisition 
phase of Morris water maze (Fig. 2.3A), WT and IL-4 KO mice both decrease in latency to find 
the hidden platform without a strain interaction (Strain effect p=0.897, Acquisition Day effect 
p<0.001, Strain x Acquisition Day effect p=0.878; Day 1 vs Day 2, 49.5 ± 2.5 vs 40.1 ± 3.7, 
p=0.336; Day 1 vs Day 3, 49.5 ± 2.5 vs 29.3 ± 5.3, p=0.004; Day 1 vs Day 4, 49.5 ± 2.5 vs 25.1 
± 4.1, p<0.001; Day 2 vs Day 3, 40.1 ± 3.7 vs 29.3 ± 5.3, p=0.213; Day 2 vs Day 4, 40.1 ± 3.7 vs 
25.1 ± 4.1, p=0.043; Day 3 vs Day 4, 29.3 ± 5.3 vs 25.1 ± 4.1, p=0.870).  In the probe trial (Figs. 
2.3B-2.3D), WT and IL-4 KO mice do not differ in % time spent in platform quadrant (WT vs 
IL-4 KO, 46.8 ± 6.4 vs 47.1 ± 6.1, p=0.972), latency to platform (WT vs IL-4 KO, 34.9 ± 6.9 vs 
29.6 ± 7.2, p=0.603) or number of platform crossings (WT vs IL-4 KO, 3.1 ± 0.9 vs 2.3 ± 0.7, 
p=0.454).  Fig. 2.3E demonstrates that WT and IL-4 KO mice both spend significantly more % 
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time investigating an object in a novel location (WT Novel vs Familiar Location, 57.6 ± 1.9 vs 
42.4 ± 1.9, p<0.001; IL-4 KO Novel vs Familiar Location, 60.4 ± 4.0 vs 39.6 ± 4.0, p=0.003).  
Fig. 2.3F shows that WT and IL-4 KO mice both investigate a novel object preferentially over a 
familiar object (WT Novel vs Familiar Object, 70.2 ± 2.5 vs 29.8 ± 2.5, p<0.001; IL-4 KO Novel 
vs Familiar Object, 66.7 ± 3.4 vs 33.3 ± 3.4, p<0.001).   
  
Anxiety-like behaviors differ in IL-4 KO versus WT mice- Fig. 2.4A shows IL-4 KO mice 
spend significantly less time in the open arms of the elevated zero maze than WT controls (WT 
vs IL-4 KO, 62.8 ± 10.0 vs 24.4 ± 6.5, p=0.003).  Figs. 2.4B and 2.4C demonstrate that while 
WT and IL-4 KOs move the same distance in the open field test (WT vs IL-4 KO, 3491.1 ± 
156.0 vs 3275.1 ± 143.9, p=0.338), the IL-4 KO mice spend significantly more time in the center 
(non-shadowed) area than WT animals (WT vs IL-4 KO, 47.9 ± 9.2 vs 76.2 ± 8.0, p=0.048). 
 
Discussion 
Burrowing food and other material is an innate behavior in rodents that is easily 
performed in a laboratory setting (Deacon, 2006), and used as a measure of generalized 
alterations (Deacon, 2009; Jirkof et al., 2013) suggestive of potential disturbances in pain (Jirkof 
et al., 2010) and depressive-like (Lavin et al., 2011) and anxiety-like behaviors (Bailey and 
Crawley, 2009).  We found that IL-4 KO mice burrow significantly less food from a burrow 
placed in their home cage than WT controls (Fig. 2.1A).  Additionally, adult mice will explore a 
novel conspecific juvenile mouse introduced into their home cage, and perturbances in this 
parameter are seen in biobehaviors such as sickness (Fu et al., 2010) or anxiety (Bailey and 
Crawley, 2009).  Fig. 2.1B demonstrates IL-4 KO mice have significantly higher exploration of a 
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novel juvenile than WT mice.  These differences in burrowing and social exploration indicate 
that there is a behavioral phenotype difference between WT and IL-4 KO animals that requires 
behavior-specific tests to identify. 
 
Assessment of depressive-like behavior in mice can be conducted using the 
sucrose/saccharin preference test and forced swim test (York et al., 2012).  In the forced swim 
test, behavioral despair is defined as reduced drive to escape and is quantified by increased 
immobility (Hales et al., 2014).  IL-4 KO mice do not differ from WT control animals in 
immobility in the forced swim test (Fig. 2.2A).  The sucrose/saccharin preference test evaluates 
loss-of-interest (anhedonia) by preference for a solution sweetened with sucrose or saccharin 
versus water (Hales et al., 2014).  No difference was observed between WT and IL-4 KO 
animals in the saccharin preference test (Fig. 2.2B).  As no anhedonia or behavioral despair is 
evident when comparing strains, IL-4 KO mice do not exhibit a depressive-like phenotype. 
 
The Morris water maze is a test used frequently in rodent models to assess spatial 
learning and memory where animals are trained and tested to use distal visual cues to locate a 
hidden, submerged escape platform (Vorhees and Williams, 2006).   In the acquisition phase, 
mice are trained in multiple trials per day starting from different positions for each trial, and 
upon completion of each trial animals are allowed to remain on the platform to orient themselves 
to the spatial cues.  Latency to platform is assessed for each trial, and impaired spatial learning is 
defined as a higher time searching for the platform over the course of the acquisition phase (York 
et al., 2012).  Fig 2.3A demonstrates that WT and IL-4 KO mice do not differ in latency to 
platform during the acquisition phase, indicating no deficit in spatial learning.  After completion 
30 
 
of acquisition, animals are tested for memory in a probe trial, where the platform is removed 
from the maze and the time spent in the platform quadrant, latency to the location previously 
occupied by the platform, and number of platform crossings are assessed (York et al., 2012).  IL-
4 KOs do not differ from WTs in time in quadrant (Fig. 2.3B), latency to platform (Fig. 2.3C) or 
number of platform crossings (Fig. 2.3D), demonstrating no difference between strains in spatial 
memory.  As previous research has suggested IL-4 KO mice display decreased cognitive 
function (Derecki et al., 2010), we sought to confirm our results with further memory testing.  
Capitalizing on the natural preference of mice for novelty, the novel object and novel location 
tests probe cognition by determining if a mouse can distinguish an unfamiliar object (non-spatial 
memory) or object placement (spatial memory) from a familiar one, respectively (Weible et al., 
2009).  A mouse should spend significantly more time exploring the novel versus the familiar 
object or location, and a deficit is defined as when exploration between the novel and familiar 
are not statistically different (York et al., 2012).  We found that WT and IL-4 KO mice both 
spend significantly more time investigating the novel versus familiar location (Fig. 2.3E) and 
object (Fig. 2.3F), suggesting no deficits in spatial or non-spatial memory and confirming 
previous results from the Morris water maze (Figs. 2.3A-D). 
 
A number of paradigms are available to test anxiety in rodents, utilizing aversive events 
or approach-avoidance conflict (Bailey and Crawley, 2009).  First we used the elevated zero 
maze (EZM), which has been shown to be a powerful model in which to study anxiety (Singh et 
al., 2007).  In the EZM, mice displaying anxiety-like behavior will spend less time in the open, 
brightly-lit versus the closed, dark arms of the maze (York et al., 2012).  We found that IL-4 KO 
mice explore the open arms of the EZM less than the WT controls (Fig. 2.4A), suggestive of 
31 
 
anxiety-like behavior of IL-4 KOs in the EZM.  To expand upon this finding, we then sought to 
determine the nature of the anxiety-like phenotype in the IL-4 KO mice.  Anxiety can be thought 
of as situation-dependent (“state” anxiety) or situation-independent (“trait” anxiety) (Bailey and 
Crawley, 2009), and may be differentiated by comparing performance on multiple anxiety tests.  
The open field test (OFT) is another common paradigm for testing anxiety (Gould et al., 2009), 
utilizing bright lights and social isolation in a novel environment.  In the OFT, in addition to 
quantifying anxiety as a reduction in time spent in the center of the testing arena, total 
locomotion can be assessed (York et al., 2012).  IL-4 KO mice do not differ from WT controls in 
total locomotion (Fig. 2.4B).  However, IL-4 KOs spend significantly more time in the center 
versus WT controls (Fig. 2.4C), which is not indicative of an anxiety like-phenotype in the OFT.  
Taken together, our results from testing anxiety-like behaviors in different paradigms suggest an 
anxiety-like phenotype in conditions specific to the EZM.  These data are in line with current 
descriptions of “state” anxiety, where animals display anxiety-like behavior only in certain 
paradigms and an anxiolytic phenotype in others (Avgustinovich et al., 2000; O'Leary et al., 
2013; Steimer, 2011).    
 
In summary, we found that IL-4 KO mice display anxiety-like behavior in the EZM (Fig. 
2.4A), but not the OFT (Fig. 2.4C), without concomitant depressive-like behavior (Figs. 2.2A-B) 
or cognitive deficits (Figs. 2.3A-F).  The results of our cognitive testing did not replicate 
previous work in IL-4 KO animals that demonstrated deficits in learning and memory (Derecki et 
al., 2010).  As we have demonstrated here that IL-4 KO animals display an anxiety-like 
phenotype that appears dependent upon the paradigm used, this may contribute to the differences 
seen between our results and those previously published.  Anxiety has been shown to affect 
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performance in cognitive tests such as the MWM (Harrison et al., 2009), and our protocol 
differed from that used in previous testing of IL-4 KOs.  Specifically, we trained and tested 
animals during their active phase (dark cycle), whereas Derecki et al. tested mice during their 
inactive phase (light cycle) (Derecki et al., 2010).  These results are not surprising in that similar 
results have been demonstrated, where a cognitive deficit was found by one group in IL-1 
receptor KO mice (Avital et al., 2003), then later an anxious phenotype without cognitive 
dysfunction was demonstrated by another group in the same strain (Murray et al., 2013).  In 
addition to reinforcing the importance of considering the complete biobehavioral profile of an 
animal and testing conditions when interpreting behavior results, our data importantly suggest a 
link between endogenous immune skew and behavior phenotype, specifically anxiety-like 
behavior.  Future research investigating the neurochemical basis for and reversibility of immune-
mediated anxiety are warranted and could lead to novel therapeutic interventions for 
neuropsychiatric complications. 
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CHAPTER 3: THE SATURATED FATTY ACID, PALMITIC ACID, INDUCES 
ANXIETY-LIKE BEHAVIOR IN MICE
3
 
 
Abstract 
 Excess fat in the diet can impact neuropsychiatric functions by negatively affecting 
cognition, mood and anxiety. We sought to show that the free fatty acid (FFA), palmitic acid, can 
cause adverse biobehaviors in mice that lasts beyond an acute elevation in plasma FFAs.  Mice 
were administered palmitic acid or vehicle as a single intraperitoneal (IP) injection. Biobehaviors 
were profiled 2 and 24 hrs after palmitic acid treatment. Quantification of dopamine (DA), 
norepinephrine (NE), serotonin (5-HT) and their major metabolites was performed in cortex, 
hippocampus and amygdala. FFA concentration was determined in plasma.  Relative fold change 
in mRNA expression of unfolded protein response (UPR)-associated genes was determined in 
brain regions.  In a dose-dependent fashion, palmitic acid rapidly reduced mouse locomotor 
activity by a mechanism that did not rely on TLR4, MyD88, IL-1, IL-6 or TNFα but was 
dependent on fatty acid chain length. Twenty-four hrs after palmitic acid administration mice 
exhibited anxiety-like behavior without impairment in locomotion, food intake, depressive-like 
behavior or spatial memory. Additionally, the serotonin metabolite 5-HIAA was increased by 
33% in the amygdala 24 hrs after palmitic acid treatment.  Palmitic acid induces anxiety-like 
behavior in mice while increasing amygdala-based serotonin metabolism. These effects occur at 
a time point when plasma FFA levels are no longer elevated. 
 
                                                          
3
 This section appeared in its entirety to Metabolism.  Moon, M. L., Joesting, J. J., Lawson, M. 
A., Chiu, G. C., Blevins, N. A., Kwakwa, K. A., Freund, G. G. (In press). The saturated fatty 
acid, palmitic acid, induces anxiety-like behavior in mice. Metabolism. 
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Introduction 
Overweight/obesity is associated with a variety of organic comorbities including 
cardiovascular disease, stroke, type 2 diabetes (T2D) and cancer (Dixon, 2010; Li et al., 2013). 
Recently, neuropsychiatric complications such as depression, cognitive impairment and anxiety 
are seen as serious adverse sequelae in overweight/obese individuals (Lopresti et al., 2013; 
Burkhalter and Hillman, 2011; Gariepy et al., 2010). Over-nutrition due to an excess intake of 
dietary fat is causally linked to the overweight/obese state (Astrup, 1999; Lissner and Heitmann, 
1995), and more recently to metaflammation-linked neurodegenerative disease (de la Monte, 
2008) and adult obstructive airway disease-associated, cognitive impairment, depression and 
anxiety (Gariepy et al., 2010; Kanoski and Davidson, 2011; Preiss et al., 2013). More recently, 
high-fat diet (HFD)-induced over-nutrition is tied to neuropsychiatric morbidities prior to the 
onset of inflammation, hyperglycemia and weight gain (Davidson et al., 2013; Kaczmarczyk et 
al., 2013) indicating that excess fat in the diet is, itself, harmful to psychological health. 
 
One consequence of a HFD is an increase in circulating free fatty acids (FFAs) (Boden, 
2011). Canonically, elevated plasma FFAs are associated with insulin resistance, non-alcoholic 
fatty liver disease (NAFLD), pre-diabetic neuropathy, decreased aortic distensibility, and 
ischemic stroke (Brands et al., 2011; Capurso and Capurso, 2012; Leamy et al., 2013; Lupachyk 
et al, 2012; Rider et al., 2012; Yaemsiri et al., 2013).Much less, however, is known about the 
impact of FFAs on the brain and behavior outside of an impact on food intake (Obici et al., 
2002). We recently demonstrated that a short-term HFD in mice impairs object-based memory 
and causes anxiety-like behavior after 1 wk of feeding, suggesting that a HFD can negatively 
impact amygdala-related processes in a relatively rapid fashion (Kaczmarczyk et al., 2013). 
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Since the brain is rich in receptors that can recognize FFAs including Toll-like receptors (TLRs) 
(Crack and Bray, 2007) and free fatty acid receptors (FFARs) (Ma et al, 2008; Nakamoto et al, 
2012), FFAs have a real potential to modulate higher brain function. 
 
Anxiety disorders, including generalized anxiety disorder (GAD), obsessive-compulsive 
disorder (OCD), panic disorder and post-traumatic stress disorder (PTSD) are among the most 
commonly reported neuropsychiatric conditions with a lifetime prevalence of nearly 29% 
(Kessler and Wang, 2008). Organically, how anxiety develops is poorly understood but 
metabolic interventions (exercise (Stathopoulou et al., 2006), weight loss (Petry et al., 2008) and 
diet modification (removal of caffeine (Smith, 1988) and alcohol (Kushner et al., 2000)) are 
often suggested as ways to reduce and/or stave off GAD or panic disorder. Given that palmitic 
acid is the most abundant saturated fatty acid in most diets (Kien et al., 2013) and its elevation in 
plasma is associated with poor clinical outcomes and disease progression for both the metabolic 
syndrome and obesity (Vessby, 2003; Mayneris-Perxachs et al., 2013), the question addressed 
here is whether FFAs can negatively impact biobehaviors in mice.  
 
Methods 
Materials- All reagents and chemicals were purchased from Sigma-Aldrich. All primers 
were purchased from Applied Biosystems. 
 
Animals- Animal use was conducted in accordance with Institutional Animal Care and 
Use Committee approved protocols at the University of Illinois. Wild-type C57BL/6J (WT), 
TLR4 knock out (KO), Myeloid differentiation primary response gene 88 (Myd88) KO, 
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interleukin (IL)-1 receptor-1 (IL-1R1) KO, IL-6 (IL-6) KO, tumor necrosis factor-α (TNF-α) KO 
mice (all on a C57BL background) were originally purchased from The Jackson Laboratory (Bar 
Harbor, ME).  Mice were group housed (8 per cage) in standard shoebox cages and provided 
water and food ad libitum, then moved to individual housing in standard shoebox cages the day 
prior to treatment unless noted otherwise. Housing temperature (72 °F) and humidity (45–55%) 
were controlled as was a 12/12 h reversed dark-light cycle (2100–0900 h). Video recording of 
animal behavior was performed under red light using a Sony HDR-XR500V Night Shot capable 
video camera (Tokyo, Japan). All treatments at each time point represent separate cohorts of 
mice, except locomotor activity which was a repeated measure. Mice used were between 8 and 
16 weeks of age. All behavior testing was completed in the dark cycle under red light 
illumination unless otherwise indicated. A total of 382 mice were used. 
  
Injectables- FFAs (palmitic acid, palmitoleic acid, myristic acid, decanoic acid, octanoic 
acid and valeric acid) were administered IP in a vehicle of castor oil at a volume of 50 µl/mouse. 
Palmitic acid was administered for the dose response at 0.3, 3, and 30 µmol/mouse, after which 
all free fatty acids (FFAs) were tested at 30 µmol/mouse. All FFA injections occurred at the 
onset of the dark cycle. 
 
Spontaneous locomotion- Locomotion was measured by videography in conjunction with 
automated video tracking software (Noldus Information Technology EthoVision XT 7 
(Leesburg, VA)), as we have described (York et al., 2013; York et al., 2012). At times indicated 
after treatment, mice were video recorded in their home cage for 5 min. Distance moved (cm) 
was determined, and results are presented as percent vehicle control.  
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Object investigation- As we have described (York et al., 2012), the subject mouse was 
placed in a novel home cage-sized arena with two objects 10 cm apart at one end. Mice were was 
video recorded for 10 min and investigative behavior of the objects was evaluated using 
EthoVision XT 7.  Results were expressed as raw investigation time (s). 
 
Zero maze- As previously described (Kaczmarczyk et al., 2013), mice were transferred 
from their home cage to the high wall section of a Zero maze, which was divided into 4 
quadrants, 2 of which had high walls (14 cm). Testing was completed under white light 
illumination and video recorded for 5 min. Time spent in the non-high wall area (open arm) was 
quantified as we have described (York et al., 2012).  
 
Food intake- As we have described (York et al., 2012), prior to treatments and, at each 
time point indicated, food was weighed.  Food intake was calculated as the difference in weight 
of food removed from the feed bowl. 
 
Forced swim test- The test mouse was transferred from its home cage to a clean white 
cylindrical PVC container (diameter 16 cm; height 31 cm) containing 20 cm of water maintained 
at 25 ± 1 °C. Total swim duration was 5 min, and immobility was evaluated from the video 
record as we have described (York et al., 2012; Park et al., 2011).  
 
Y-maze- Testing was performed as previously described (Kaczmarczyk et al., 2013; York 
et al., 2012).  The subject mouse was placed into one of the 3 maze arms. The Y-maze used was 
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symmetrical, clear and Plexiglas (arms = 40 cm in length × 9 cm in width × 16 cm in wall 
height). Maze side walls were decorated with black triangles, black circles, or black diagonal 
lines. Movement was video recorded for 5 min and scored by hand by a blinded observer. Arm 
entry required all 4 legs of the subject mouse to enter an arm. Perfect alternations were defined 
as exploration of all three arms sequentially given 3 opportunities independent of a right or left 
arm choice at initiation. Imperfect alternations were defined as entry into all three arms in 4 
opportunities. Results were calculated as the number of perfect or imperfect alternations divided 
by total opportunities. 
 
Plasma FFAs- Mice were euthanized and blood collected via cardiac puncture in BD 
Microtainer Tubes with Lithium Heparin (BD Diagnostics, Franklin Lakes, NJ) on ice.  Blood 
was centrifuged at 2,000 x g for 10 min at 4°C and plasma collected.  Plasma FFAs were 
measured on aAU680 Chemistry System (Beckman Coulter, Brea, CA) using a non-esterified 
fatty acid module (Randox Laboratories Ltd., UK). 
 
Brain region collection- As we have described (Chiu et al., 2012), mice were euthanized 
and immediately perfused through the left ventricle with 30 mL of ice-cold PBS. Brains were 
removed and regions dissected. 
 
HPLC- Mouse brain regions were solubilized as previously described (O’Connor et al., 
2009) in 0.1 N HClO4 and 25 μM ascorbate using an ultrasonic tissue disruptor (Sonics & 
Materials, Inc., Newtown, CT). Homogenates were centrifuged at 12,000 × g for 10 min at 4 °C. 
Supernatants were diluted in 0.02 N HClO4 and analyzed by HPLC for norepinephrine (NE), 
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normetanephrine (NME), 5-hydroxytrypatime (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), 
dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) using 
an ESA Coulochem III detector with a 5041 Enhanced Analytical cell containing a glassy carbon 
electrode (+320 mV) (Thermo Scientific, Sunnyvale, CA). Mobile phase (pH = 3.0) consisted of 
75 mM NaH2PO4, 25 μM EDTA (disodium salt), 0.45 mM octanesulfonic acid and 
triethylamine in acetonitrile:water (5:95, v:v) and was pumped at 0.2 µL/min through a 2 mm x 
150 mm ODS Hypersil column (Thermo Scientific, Sunnyvale, CA). Protein concentrations in 
tissue pellets were determined using the DC Protein Assay (BioRad, Hercules, CA) and read on 
ELx800 Absorbance Microplate Reader (BioTek, Winooski, VT) after being solubilized in RIPA 
buffer (150 mM NaCl, 5 mM EDTA, 0.1% SDS, 1% Triton and 10 mM Tris, pH 7.4) using a 60 
Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA). Results were quantified as ng 
analyte/mg brain region protein, and expressed as raw values and as ratios.  
 
Monoamine oxidase (MAO) activity- MAO activity was determined as previously 
described (Kaczmarczyk et al., 2013).  Briefly, brain regions were freeze fractured and 
homogenized in reaction buffer containing 50 mM NaCl (Fisher Scientific, Fair Lawn, NJ), 10% 
glycerol, 1 mM EDTA, 50 mM HEPES, pH 7.4 (USB Corporation, Cleveland, OH). Lysates 
were clarified at 16,000 × g for 15 min at 4 °C and the supernatant protein concentrations 
determined using the DC Protein Assay (Bio-Rad, Hercules, CA) as above. Sample protein 
concentrations were normalized within regions with reaction buffer. MAO activity was tested 
using the MAO-Glo Assay System (Promega, Madison, WI) and quantified with an ImageQuant 
LAS-4000 CCD camera quantitative imager (GE Healthcare, Piscataway, NJ) coupled to Multi 
Gauge Software (GE Healthcare, Piscataway, NJ). 
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qPCR- RNA was extracted, cDNA generated, and gene expression was determined as 
previously described (Kaczymarczyk et al., 2013). In brief, mRNA was reverse transcribed using 
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan Gene 
Expression primer for X-box binding protein 1 (Xbp1) (Mm00457357_m1), ER degradation 
enhancer mannosidase alpha-like 1 (Edem1) (Mm00551797_m1), heat shock protein 90 beta 
member 1 (Hsp90b1) (Mm00441926_m1) and activating transcription factor 4 (Atf4) 
(Mm00515325_g1) were used in real-time PCR performed on a 7900 HT Fast Real-Time PCR 
System (Applied Biosystems) using TaqMan Universal PCR Master Mix. Parallel amplification 
of GAPDH (Mm00484668_m1) was performed to normalize gene expression. Relative fold 
change of target genes was performed by comparing ΔCts.  
 
Statistics- Data are expressed as mean ± SEM. Data analysis was conducted using Sigma 
Plot 11.2 (Systat Software, Chicago, IL). One-way or two-way ANOVA were run with or 
without repeated measurements where needed. Tukey’s test was used for post-hoc comparison 
procedures. All statistical analysis included testing for treatment x time interactions. Statistical 
significance was determined as p<0.05. 
 
Results 
Palmitic acid decreases spontaneous locomotion- Fig. 3.1 demonstrates that 30 and 3 
µmol, but not 0.3 µmol, of IP-administered palmitic acid induces a decrease in locomotion 2 h 
after injection compared to vehicle-treated controls (Treatment effect p<0.001; 30 µmol vs. 
vehicle, 26.5% ± 5.1 vs 100% ± 5.8, p<0.001; 3 µmol vs. vehicle, 58.1% ± 3.73 vs. 100% ± 5.8, 
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p=0.002; 0.3 µmol vs. vehicle, 105.7% ± 11.5 vs. 100% ± 5.8, p=0.947). The effect of palmitic 
acid on locomotion is dependent on dose (30 vs. 3 µmol, p=0.019).  
 
Palmtic acid-induced loss of locomotion is not dependent on TLR4, MyD88, IL-1, IL-6 or 
TNFα- Fig. 3.2 shows that palmitic acid decreased locomotion 2 h after IP administration in 
WT,TLR4, MyD88, IL-1R1, IL-6 and TNFα KO mice (TLR4 KO vehicle vs. palmitic, 100.0 ± 
7.9 vs. 45.7 ± 5.5, p<0.001; MyD88 KO vehicle vs. palmitic, 100.0 ± 8.5 vs. 41.5 ± 4.2, p<0.001; 
IL-1R1 KO vehicle vs. palmitic, 100.0 ± 8.7 vs. 52.9 ± 8.9, p=0.002; IL-6 KO vehicle vs. 
palmitic, 100.0 ± 8.7 vs. 38.3 ± 6.5, p<0.001; TNFα KO vehicle vs. palmitic, 100.0 ± 7.1 vs. 36.1 
± 10.0, p<0.001).The decrease observed in KO animals was not different than WT (data not 
shown; WT vs. TLR4 KO strain x treatment p=0.804; WT vs. MyD88 KO strain x treatment 
p=0.890; WT vs. IL-1R1 KO strain x treatment p=0.089; IL-6 KO strain x treatment p=0.696; 
WT vs. TNFα KO strain x treatment p=0.337).   
 
Chain length is important to FFA-dependent loss of spontaneous locomotion- Fig. 3.3 
shows that IP-administered palmitic acid (16:0), palmitoleic acid (16:1), myristic acid (14:0) and 
decanoic acid (10:0) reduced locomotion at 2 h (vehicle vs. palmitic, 100.0 ± 7.8 vs. 31.4 ± 2.4, 
p<0.001; vehicle vs. palmitoleic, 100.0 ± 7.8 vs. 29.0 ± 4.5, p<0.001; vehicle vs. myristic, 100.0 
± 7.8 vs. 27.4 ± 4.8, p<0.001; vehicle vs. decanoic, 100 ± 7.8 vs. 53.9 ± 4.5, p<0.001). Loss of 
locomotion caused by palmitoleic, myristic and decanoic acids were not different from palmitic 
acid (palmitic vs. palmitoleic, 31.4 ± 2.4 vs. 29.0 ± 4.5, p=1.000; palmitic vs. myristic, 31.4 ± 2.4 
vs. 27.4 ± 4.8, p=1.000; palmitic vs. decanoic, 31.4 ± 2.4 vs. 53.9 ± 4.5, p=0.064). Locomotion 
after administration of octanoic acid (8:0) and valeric acid (5:0) was not different from vehicle 
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(vehicle vs. octanoic, 100 ± 7.8 vs. 87.3 ± 6.8, p=0.631; vehicle vs. valeric, 100.0 ± 7.8 vs. 78.1 
± 5.0, p=0.078) and was significantly greater than that seen for the other FFAs administered 
(octanoic vs. palmitic, 87.3 ± 6.8 vs. 31.4 ± 2.4, p<0.001; octanoic vs. palmitoleic, 87.3 ± 6.8 vs. 
29.0 ± 4.5, p<0.001; octanoic vs myristic, 87.3 ± 6.8 vs. 27.4 ± 4.8, p<0.001; octanoic vs. 
decanoic, 87.3 ± 6.8 vs. 53.9 ± 4.5, p=0.001; valeric vs. palmitic, 78.1 ± 5.0 vs. 31.4 ± 2.4, 
p<0.001; valeric vs. palmitoleic, 78.1 ± 5.0 vs. 29.0 ± 4.5, p<0.001; valeric vs. myristic, 78.1 ± 
5.0 vs. 27.4 ± 4.8, p<0.001; valeric vs. decanoic, 78.1 ± 5.0 vs. 53.9 ± 4.5, p=0.036). 
 
Mice exhibit anxiety-like behavior 24 hrs after palmitic acid administration- Figs. 3.4A 
and 3.4B show that palmitic acid induces a decrease in time spent investigating an unfamiliar 
object (vehicle vs palmitic, 41.7%  ± 4.8 vs 23.6% ± 4.8, p=0.013) and a decrease in time spent 
in the open arm of a Zero maze (vehicle vs palmitic, 54.4 sec ± 6.1 vs 35.4 sec ± 3.2, p=0.015) at 
24 h after treatment, which resolves by 48 h (vehicle vs palmitic, 54.6 sec ± 7.0 vs 56.0 sec ± 
6.3, p=0.886). Fig. 3.4C demonstrates that there is a decrease in locomotion 2 h after palmitic 
acid administration, and that locomotion in palmitic acid-treated mice is not different from 
controls at 24 h post treatment (treatment x time effect, p<0.001; 2 h vehicle vs 2 h palmitic, 
100% ± 2.9 vs 37.2% ± 9.0, p<0.001; 24 h vehicle vs 24 h palmitic, 100% ± 9.1 vs 80.2% ± 9.0, 
p=0.102; 2 h palmitic vs 24 h palmitic, 37.2% ± 9.0 vs 80.2% ± 9.0, p<0.001). Fig. 3.4D 
illustrates that food intake decreases in palmitic acid-treated animals in the 24 h interval after 
administration, and increases to levels seen in controls from 24 to 48 h after treatment (treatment 
x time effect, p<0.001; 0 to 24 h vehicle vs 0 to 24 h palmitic, 3.1 g ± 0.17 vs 0.9 g ± 0.4, 
p<0.001; 24 to 48 h vehicle vs 24 to 48 h palmitic, 3.2 g ± 0.1 vs 2.5 g ± 0.2, p=0.061, 0 to 24 h 
palmitic vs 24 to 48 h palmitic, 0.9 g ± 0.4 vs 2.5 g ± 0.2, p<0.001). Figs. 3.4E and 3.4F show 
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that at 24 h after administration, palmitic acid-treated mice do not display differential immobility 
in the forced swim test (vehicle vs palmitic, 107.0 sec ± 8.1 vs 113.3 sec ± 15.7, p=0.731) or Y-
maze perfect alternations (vehicle vs palmitic, 61.7% ± 1.9 vs 62.3% ± 4.0, p=0.894).   
 
Palmitic acid increases the serotonin metabolite 5-HIAA in the amygdala- Table 3.1 
shows that 24 hrs after palmitic acid administration mice had a33% increase in 5-HIAA in the 
amygdala. Table 3.2 demonstrates that 24 hrs after palmitic acid administration there was a25% 
decrease in the 5-HT:5-HIAA ratio in the amygdala and a 42% increase in the DA:DOPC ratio in 
the hippocampus. Table 3.3 shows no difference in brain MAO-A or MAO-B activity 24 hrs 
after palmitic acid administration. Fig. 3.5 shows that 24 hrs after palmitic acid administration 
plasma FFAs were no longer elevated (treatment x time effect p=0.038; 2 h vehicle vs 2 h 
palmitic, 0.88 mmol/l ± 0.17 vs 1.63 mmol/l ± 0.10, p<0.001; 4 h vehicle vs 4 h palmitic, 0.76 
mmol/l ± 0.09 vs 1.76 mmol/l ± 0.09, p<0.001; 8 h vehicle vs 8 h palmitic, 0.94 mmol/l ± 0.17 vs 
1.45 mmol/l ± 0.21, p=0.018; 12 h vehicle vs 12 h palmitic, 1.00 mmol/l ± 0.09 vs 1.45 mmol/l ± 
0.13, p=0.026; 24 h vehicle vs 24 h palmitic, 0.70 mmol/l ± 0.17 vs 0.83 mmol/l ± 0.13, 
p=0.511). 
 
Genes associated with the un-folded protein response (UPR) are not up-regulated by 
palmitic acid in the brain- Table 3.4 demonstrates gene expression of Xbp1, Edem1, Hsp90b1 
and Atf4 24 hrs after palmitic acid administration, in the cortex, hippocampus and amygdala. 
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Discussion 
Over-nutrition predisposes individuals to a variety of adverse outcomes including 
neuropsychiatric sequelae (Dixon, 2010; Li et al., 2013; Lopresti and Drummond, 2013; 
Burkhalter and Hillman, 2011; Gariepy, 2010). Furthermore, especially in obesity, elevated 
plasma FFAs correlate with certain psychological alterations (Kien, 2009; Tsuboi et al., 2013). 
While circulating FFAs are implicated in the development of morbidities associated with a 
western-style HFD, the mechanisms underlying the complications of an obesogenic diet and the 
role of FFAs is still unclear (Kaczymarczyk et al., 2013; Lupachyk et al., 2012; Wen et al., 2011; 
Eguchi et al., 2012). Inflammation is a well-described consequence of over-nutrition and is a 
potential mechanism by which HFDs can trigger insulin resistance, diabetes and diabesity-related 
co-morbid conditions (Gregor and Hotamisligil, 2011). Acute inflammation, through pro-
inflammatory cytokines, causes sickness behaviors such as reduced locomotion, anorexia, 
memory impairment and anxiety (Dantzer et al., 2008). Therefore, given that FFAs can drive a 
pro-inflammatory phenotype in astrocytes, microglia and neuronal stem cells (Gupta et al., 2012; 
Tracy et al., 2013; Yuan et al., 2013), pro-inflammatory cytokines would seem a likely 
antecedent to adverse behaviors induced by FFAs. Here we show that TLR4 KO, MyD88 KO, 
IL-1R1 KO, IL-6 KO and TNFα KO mice all developed an FFA-dependent reduction in 
spontaneous locomotion. These finding indicate that the canonical pathway of FFAs binding to 
TLR4 (Lee et al., 2001; Yin et al., 2013) inducing classical macrophage activation (Moon et al., 
2011) with elaboration of IL-1, IL-6 and TNF- is not responsible for the behaviors observed. 
While these findings do not exclude inflammation as a mechanism by which FFAs can adversely 
impact the brain, they do indicate that FFAs serving as a LPS lipid A analog in the stimulation of 
TLRs, especially TLR4, is not a likely mechanism by which FFAs promotes anxiety. Further 
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evidence that canonical inflammatory pathways may not be directly involved in the 
biobehavioral impact of administered FFAs is that both saturated palmitic acid, and 
monounsaturated palmitoleic acid induced loss of locomotion, as did the long chain FFA, 
myristic acid, and the longer medium chain FFA, decanoic acid. Work in vitro comparing 
unsaturated FFAs with saturated FFAs demonstrate that the unsaturated FFAs are ineffective at 
generating a classical inflammatory response in macrophage-derived cells when TNF 
generation is examined (Lee et al., 2001). Interestingly, the short chain FFA, valeric acid, and the 
shorter medium chain FFA, octanoic acid, did not affect locomotion at the times measured 
suggesting that fatty acid chain length and not saturation are important to the biobehaviors 
observed. 
 
Since TLRs did not appear responsible for the behaviors observed and FFA chain length 
impacted efficacy, a potential mechanism by which certain FFAs could trigger the effects seen is 
via FFAR1. FFAR1-3 are a closely related family of receptors that were previously identified as 
the orphan G-protein receptor (GPR)s: GPR40, GPR43 and GPR41, respectively (Stoddart et al., 
2008). In 2003, a variety of groups identified free fatty acids as the ligands for these GPRs 
(Stoddart et al., 2008). Medium and long chain fatty acids were the agonists for FFAR1 while 
short chain fatty acids, with a chain length of less than 6 carbons, were the agonists for FFAR2 
and FFAR3 (Stoddart et al., 2008). Briscoe et al. characterized the ability of 42 different long-
chain FFAs to activate FFAR1 in FFAR1 transfected HEK293 cells via measurement of 
intracellular calcium ([Ca2+]i) release because FFAR1 after binding fatty acids activates 
phospholipase C (PLC) raising [Ca2+]i. In support, palmitic acid was one of the most potent 
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activators of FFAR1 with an EC50 of 10 M. Tissue distribution of FFAR1 is relatively 
ubiquitous with the highest mRNA expression in the brain (Briscoe et al., 2003). 
 
While longstanding overnutrition is linked to alterations in brain function and 
neuropsychiatric complications (de la Monte and Wands, 2008; Bruce-Keller et al., 2009), short-
term overnutrition, in both rodents and humans, can also generate adverse biobehaviors. These 
neuropsychiatries include cognitive dysfunction, attention disorders and anxiety-like behaviors. 
Short-term HFD feedings appear particularly detrimental to attention, spatial memory and 
anxiety and tends to manifest prior to the clear onset of metabolic dysfunction (Kaczymarczyk et 
al., 2013; Edwards et al., 2011; Murray et al., 2009; Valladolid-Acebes et al., 2011). To 
investigate the possibility that a single exposure to FFAs could precipitate such biobehavioral 
changes, we utilized the forced swim test, Y-maze, object investigation and elevated Zero maze 
to probe FFA-treated mice for depressive-like behavior, spatial memory defects, and anxiety-like 
behavior, respectively. We found that palmitic acid induced anxiety-like behavior that could be 
measured 24 hrs post administration which was a time point at which palmitic acid-dependent 
impairments in locomotion and food intake had resolved. This time frame fits well with human 
fear/anxiety paradigms because these emotions frequently manifest/persist well beyond the 
putative eliciting event and are commonly unassociated with memory impairment and depression 
(Milanak et al., 2013).   
 
An important reason why we were able to identify the FFA-dependent behaviors 
observed was likely due to how we administered the FFAs. Since Lee et al. first demonstrated 
that saturated fatty acids activate TLR4 (Lee et al., 2001), investigators in the field have 
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generally prepared saturated free fatty acids as 10:1 saturated free fatty acid: albumin complexes 
in ethanol because saturated FFAs are insoluble in most physiologically relevant aqueous 
solutions. Albumin has a high affinity for saturated FFAs (10
-7
 for palmitic acid, as example) 
(Spector, 1975) and this high-affinity can hinder FFA bioavailability and FFA-dependent 
activation of FFAR1, as shown by Stoddart et al. (Stoddart et al., 2007). Therefore, instead of 
using the method of Lee et al. in our preparations of palmitic acid, we used a novel oil-in-oil 
delivery system with castor oil as the carrier. This approach potentially enabled improved FFA 
bioavailability. In addition, we did not have to deliver ethanol which confounds behavioral 
testing and has anxiolytic properties (Gilles et al., 2006). Importantly, we administered a 
relatively low dose of palmitic acid that caused only a doubling of plasma FFAs. This level of 
FFA is often seen after an ingestion of a high-fat meal or a short-term fast (Dole, 1956).    
 
Dysfunctional neurotransmitter availability and signaling is associated with many 
neuropsychiatric sequelae, including memory loss, depression, delirium and anxiety (Blier and El 
Mansari, 2013; Gressier et al., 2013; Johansen et al., 2011). Recently, we demonstrated that mice 
fed a HFD for 1 wk exhibit memory impairment and anxiety like behaviors that were connected 
to disrupted brain-based dopamine metabolism (Kaczymarczyk et al., 2013). Here we found that 
24 hrs after palmitic acid administration the hippocampal DA:DOPAC ratio was elevated in the 
hippocampus and that the 5-HT:5-HIAA ratio was elevated in the amygdala. This dopamine ratio 
supports the contention that FFAs may be responsible for HFD-mediated dysregulated dopamine 
metabolism in the brain and that the addictive nature of HFDs may be related to perturbed brain 
levels of dopamine (Vucetic and Reyes, 2010). Previously, in our HFD feeding work, we did not 
look at the amygdala or at serotonin/serotonin metabolism. In that the amygdala is critical to 
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emotive learning (Hamann et al., 1999) and anxietal states (Davis, 1992) and defects in 
serotonergic signaling in the amygdala are associated with anxiety (Matsuda, 2013), our current 
findings suggest that palmitic acid-dependent increase in 5-HIAA may be responsible for the 
anxiety seen. Correlatively, increased 5-HIAA in the amygdala is associated with anxiety-like 
behavior in mice (Neufeld-Cohen et al., 2010). Recently it has been noted that palmitic acid can 
be lipotoxic to cells resulting in an accumulation of reactive oxygen species (ROS) (Egnatchik et 
al., 2014) that fosters endoplasmic reticulum (ER) stress (Havashi et al., 2014) and subsequent 
apoptosis (Shen et al., 2014). Additionally, ER stress has been implicated in the FFA-induced 
complications of obesity (Boden, 2009; Melo et al., 2014). To determine if ER stress is involved 
in the observed neurotransmitter alterations and anxiety-like behavior, we quantified changes in 
expression of genes downstream of the ER stress response (van Galen et al., 2014). No 
upregulation of genes associated with ER stress signaling were found, suggesting that ER stress 
and lipotoxicity in the brain are not responsible for the anxiety-like behaviors demonstrated in 
our model. 
 
Our data demonstrate an acute lasting behavioral response to the FFA, palmitic acid, 
which appears distinct from overnutrition-associated comorbidities driven by canonical 
inflammatory pathways.  These data are the first to show that palmitic acid administration is 
anxiogenic and suggest that modest serum elevations in long-chain FFAs may underlie 
neuropsychiatric complications observed in metabolic diseases like obesity and T2D.  Further 
exploration into the metabolic origins of anxiety is warranted with serum long-chain FFAs an 
intriguing new bioactive.  Therefore, elucidating metabolic mechanisms that contribute to mental 
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illness will likely yield promising biomarkers and drug targets to diagnosis and treat a variety of 
psychiatric illnesses. 
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CHAPTER 4: CONCLUSION 
 
Summary 
We hypothesized that an imbalance in immune mediators would result in an altered 
biobehavioral phenotype in mice (Moon et al, 2011).  Through the IL-4 KO model of 
endogenous immune skew, we demonstrated an altered behavioral profile in naïve animals, 
characterized by exhibition of anxiety-like behavior in a context-dependent manner (Moon et al., 
In Process).  Further, we demonstrated exogenous administration of a ubiquitous compound, 
palmitic acid, could also induce anxiety-like behavior in mice (Moon et al., 2014).  These data 
are collectively the first to show 1) the biobehavioral phenotype of IL-4 KO mice and 2) the 
biobehavioral phenotype resulting from acute administration of palmitic acid.  Importantly, these 
results indicate that anxiety can be precipitated by diverse stimuli, suggesting a common 
pathway to eliciting anxiety-like behaviors. 
 
Pitfalls and Future Directions 
 While novel pathways inducing anxiety-like behaviour have been suggested based on this 
work, we did not definitively identify the pathways involved.  A critical next step is to determine 
the mechanisms behind the biobehavioral phenotypes we have described in our models.   
 
In the biobehavioral phenotype of IL-4 KO animals, a neurological correlate has not been 
identified.  While we found context-specific anxiety-like behavior in IL-4 KO mice, we did not 
identify changes in brain structure, cellular function, or neurotransmitter levels in these animals.  
Further research remains to investigate the mechanisms behind the behaviour alterations and if 
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these behaviors are chemically reversible or due to permanent functional changes.  Additionally, 
we did not investigate the effect on circadian rhythm of IL-4 depletion, as this could influence 
the behaviors noted in the animals due to shifts in activity levels.  Also, while we identified a 
role for IL-4 in development of biobehavioral disturbances, we did not localize the effect to a 
specific cell type.  Generating animals without IL-4 receptor (IL-4R) on specific cell types using 
Cre-Lox recombination could identify cell types involved in the unique behaviour phenotype 
associated with lack of IL-4.  Irrespective of the cell type involved, ameliorating the anxiety-like 
behaviour in the IL-4 KO animals was not achieved.  Previous research using IL-4 KO mice has 
found resolution of behavior changes through adoptive transfer of immune cells from WT 
animals (Derecki et al., 2010).  Repletion of IL-4 by adoptive transfer of WT immune cells or 
administration of exogenous IL-4 in IL-4 KO animals would be beneficial to understanding the 
role of this cytokine in biobehavior.  
 
In the palmitic acid administration paradigm, a signalling location and receptor remains 
to be defined.  Some potential sites of sensing the exogenous palmitic acid that were not 
investigated could be the vagus nerve or hypothalamus.  Vagal sensing of peritoneal contents is a 
common pathway for other immune-mediated biobehavioral responses (Dantzer et al., 2008) and 
could be probed using animal with a sub-diaphragmatic vagotomy.  Should vagotomised mice 
still respond to palmitic acid administration, it is likely that the signal is relayed directly to the 
brain.  The hypothalamus is a likely candidate, as it is rich in FFAR1, a receptor that can bind 
palmitic acid (Nakamoto et al., 2012).  However, whether these signals are propagated by 
FFARs, as we proposed based on the FFA panel (Fig. 3.3), or other mechanisms also remains 
unanswered. An inhibitor of FFAR1 was not available at the initiation of these studies.  
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However, the FFAR1 antagonist GW1100 has recently become commercially available and 
would be useful to determine the role of FFAR1 in this paradigm.  Studies using intraperitoneal 
versus intracerebroventricular injection of the antagonist would not only determine if FFAR1 
plays a role in palmitic acid-induced anxiety, but would also be an important indicator of 
peripheral versus central FFA signalling.  Additionally, generation of FFAR1 KO animals, 
especially utilizing Cre-Lox recombination technology to generate cell-specific KOs, would be 
an important next step in identifying the cellular response in palmitic acid treatment.  Lastly, 
direct treatment of the responsive cells with palmitic acid in culture would conclude this course 
of study by delineating the signalling cascade in response to FFAs. 
 
Clinical Implications 
 Psychological pathologies are complex states that contribute significantly to suffering, 
yet the neurological basis of these disorders are often not well understood, hindering efforts at 
pharmacologic intervention.  Of the neuropsychiatric conditions, anxiety disorders affect nearly 
one third of the population (Kessler and Wang, 2008).  Research currently suggests a potential 
role for most of the neurotransmitter systems in the pathogenesis of anxiety (Bukalo et al., 2014), 
with serotonin signalling/metabolism (Matsuda 2013; Neufeld-Cohen et al., 2010) being the 
most well-studied candidate.  Approved pharmacologic treatment of anxiety currently includes 
benzodiazepines, monoamine oxidase inhibitors, tricyclic antidepressants, and selective 
serotonin and norepinephrine reuptake inhibitors (Bukalo et al., 2014).  However, given the 
diverse mechanisms of action of these treatments, anxiety pharmacotherapy is not well defined.  
Our research demonstrates that anxiety-like behaviour can develop in two unrelated animal 
models, one of endogenous immunologic skew and the other of free fatty acid administration.  
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Further research delineating the mechanisms behind the anxiety-like behaviors we observed 
would advance the understanding of the pathogenesis of anxiety and could potentially yield 
novel therapeutic interventions. 
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FIGURES AND TABLES 
 
 
Fig.1.1 Macrophage (MΦ) phenotype skew is a product of multiple influences. T helper (Th) and 
other immune cells produce cytokines that influence macrophage activation states. Pathogen-
associated molecular patterns (PAMPs) and IFNγ from Th 1 and natural killer (NK) cells 
synergize to generate M1 MΦs. Neutrophil and Th2 cell IL-4 and IL-13 prime M2 MΦs.  
Glucocorticoids, prostaglandins and regulatory T cell (Treg) TGF-β and IL-10 deactivate MΦs, 
and dMΦ-produced IL-10 feeds-back to enhance the deactivated phenotype. 
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Table 1.1  Characteristic markers of the 3 main MΦ phenotypes.  M1 MΦs express high levels 
of iNOS and proinflammatory cytokines to fight invading microorganisms.  M2 MΦs exhibit a 
gene profile conducive to wound healing and produce anti-inflammatory IL-1ra.  A high IL-
10/IL-12 ratio in dMΦs promotes resolution of inflammation through decreasing cytotoxic cell 
generation and proinflammatory cytokine actions. 
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Fig. 2.1 IL-4 KO mice display burrowing and social exploration differences.  (A) C57BL/6J 
mice (WT) and IL-4 KO mice were allowed free access to a food pellet-filled burrow and 
contents were assessed 10 h later.  Results are expressed as means ± s.e.m.; n=14-16, *p<0.05.  
(B) Novel conspecific juvenile mice were introduced into the home cage of WT and IL-4 KO 
mice for 5 min and investigation of the juvenile by test mouse was quantified.  Results are 
expressed as means ± s.e.m.; n=18, *p<0.05. 
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Fig. 2.2 IL-4 KO mice do not exhibit depressive-like behavior.  (A) WT and IL-4 KO mice were 
subjected to the forced swim test for 5 min and total immobility was quantified.  Results are 
expressed as means ± s.e.m.; n=7-9, *p<0.05.  (B) WT and IL-4 KO mice were allowed free 
access to water and a 0.4% saccharin solution for 24 h.  Quantities of each fluid were recorded 
and saccharin consumption expressed as the percent of total fluid consumption.  Results 
expressed as means ± s.e.m.; n=17-18, *p<0.05.  
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Fig. 2.3 Spatial and non-spatial memory is not impaired in IL-4 KO mice.  (A) WT and IL-4 KO 
mice were trained in the Morris Water Maze at 3 trials per day for 4 days.  Latency to platform 
was quantified for each trial, and results are the average of 3 trials for each day.  Results are 
expressed as means ± s.e.m.; n=8, *p<0.05.  (B-D) On the 5th day of testing in the Morris Water 
Maze, the hidden platform was removed and mice were tested in 3 trials of 60 seconds.  Time 
spent in platform quadrant (B), latency to platform (C) and number of platform crossings  
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Fig. 2.3 (cont.) (D) were quantified for each trial, and results are the average of 3 trials.  Results 
are expressed as means ± s.e.m.; n=8, *p<0.05.  (E)  WT and IL-4 KO mice were subjected to 
Novel Location test for 5 min.  Exploration of objects was quantified and investigation of each 
location expressed as percent of total investigation time.  Results are expressed as means ± s.e.m; 
n=7-9, *p<0.05.  (F)  WT and IL-4 KO mice were subjected to Novel Object test for 5 min.  
Exploration of objects was quantified and investigation of each object expressed as percent of 
total investigation time.  Results are expressed as means ± s.e.m.; n=16, *p<0.05.   
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Fig. 2.4 Anxiety-like behaviors differ in IL-4 KO versus WT mice.  (A) WT and IL-4 KO mice 
were tested in the Elevated Zero Maze for 5 minutes and time spent in open arms of the maze 
was quantified.  Results are expressed as means ± s.e.m; n=15, *p<0.05.  (B-C)  WT and IL-4 
KO mice were allowed to explore an open field arena for 5 minutes.  Total locomotor activity 
and time spent in center of arena were quantified.  Results are expressed as means ± s.e.m; n=5, 
*p<0.05.  
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Fig. 3.1 Palmitic acid decreases spontaneous locomotor activity. Mice were injected 
intraperitoneal (IP) with vehicle or palmitic acid (0.3, 3 or 30 µmol) and home-cage locomotion 
was measured 2 h later.  Results are expressed as means ± s.e.m.; n=8-9.  Bars without a 
common superscript are different (p<0.05). 
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Fig. 3.2 Palmitic acid-induced loss of locomotion is not dependent on TLR4, MyD88, IL-1, IL-6 
or TNFα. C57BL/6J mice (WT) and mice with a genetic knock-out (KO) of TLR4, MyD88, IL-
1r1, IL-6, and TNFα were injected IP with vehicle or 30 µmol palmitic acid and home-cage 
locomotion was measured 2 h later.  Results are expressed as means ± s.e.m.; n = 7-12. (*p<0.05 
vs vehicle treated control). 
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Fig. 3.3 Chain length is important to FFA-dependent loss of spontaneous locomotion. Wild type 
(WT) mice were injected IP with vehicle or 30 µmol of palmitic (C16:0), palmitoleic (C16:1), 
myristic (C14:0), decanoic (C10:0), octanoic (C8:0) or valeric (C5:0) acid and home-cage 
locomotion was measured 2 h post-injection. Results are expressed as means ± s.e.m.; n = 8. 
Bars without a common superscript are different (p< 0.05). 
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Fig. 3.4 Mice exhibit anxiety-like behavior 24 hrs after palmitic acid administration. 
65 
 
Fig. 3.4 (cont.) (A) Mice were injected IP with vehicle or 30 µmol palmitic acid and time spent 
investigating novel objects in a test arena was quantified. Results are expressed as means ± 
s.e.m.; n = 7. (*p < 0.05 versus vehicle treated control). (B) Mice were injected IP with vehicle or 
30 µmol palmitic acid and time spent in the open arm of the elevated Zero maze was quantified 
24 and 48 hrs post-treatment. Results are expressed as means ± s.e.m.; n = 8. (*p<0.05 versus 
vehicle treated control per time). (C) Mice were injected IP with vehicle or 30 µmol palmitic 
acid and home-cage locomotion was measured 2 and 24 h later. Results are expressed as means ± 
s.e.m.; n = 11-14. Bars without a common superscript are different (p< 0.05). (D) Mice were 
injected IP with vehicle or 30 µmol palmitic acid and food intake was measured from injection to 
24 h and from 24 h to 48 h. Results are expressed as means ± s.e.m.; n = 9-10. Bars without a 
common superscript are different (p< 0.05). (E) Mice were injected IP with vehicle or 30 µmol 
palmitic acid and FST immobility was scored after 24 h. Results are expressed as means ± s.e.m.; 
n = 4. (*p < 0.05 versus vehicle treated control). (F) Mice were injected IP with vehicle or 30 
µmol palmitic acid and Y-maze performance was scored at % perfect alternations after 24 h. 
Results are expressed as means ± s.e.m.; n = 8. (*p<0.05 versus vehicle treated control).  
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Fig. 3.5 Plasma FFAs levels after palmitic acid administration. Mice were injected IP with 
vehicle or 30 µmol palmitic acid and plasma FFAs were measured at 2, 4, 8, 12 or 24 h later. 
Results are expressed as means ± s.e.m.; n = 6. Bars without a common superscript are different 
(p<0.05).  
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Table 3.1 - NE, NME, DA, DOPAC, HVA, 5-HT and 5-HIAA concentrations in the brain 24 h after palmitic 
acid administration 
 
                 Cortex     Hippocampus        Amygdala 
Vehicle Palmitic Vehicle Palmitic Vehicle Palmitic 
NE   2.34 ± 0.08   2.36 ± 0.13   2.28 ± 0.07   2.44 ± 0.12   3.28 ± 0.17   3.43 ± 0.41 
NME   0.42 ± 0.05   0.33 ± 0.05   0.45 ± 0.05   0.38 ± 0.05   0.29 ± 0.06   0.38 ± 0.05 
DA   8.49 ± 1.12   9.52 ± 0.95   0.07 ± 0.01   0.10 ± 0.02   1.12 ± 0.13   1.12 ± 0.13 
DOPAC   1.27 ± 0.08   1.15 ± 0.11   0.08 ± 0.01   0.07 ± 0.01   0.29 ± 0.04   0.28 ± 0.03 
HVA   1.59 ± 0.13   1.79 ± 0.16   0.28 ± 0.02   0.29 ± 0.03   0.43 ± 0.07   0.47 ± 0.07 
5-HT   1.69 ± 0.06   1.70 ± 0.08   1.70 ± 0.24   1.91 ± 0.23   5.96 ± 0.37   5.89 ± 0.53 
5-HIAA   1.01 ± 0.05   1.07 ± 0.04   2.75 ± 0.15   3.01 ± 0.21   2.01 ± 0.16   2.67 ± 0.24* 
Results are expressed as means; n=5-6.  Significant difference at *p<0.05 vs vehicle. 
 
Table 3.2 – NE:NME, DA:DOPAC, DA:HVA and 5-HT:5-HIAA concentrations in the brain 24 h after 
palmitic acid administration 
 
Cortex Hippocampus Amygdala 
Vehicle Palmitic Vehicle Palmitic Vehicle Palmitic 
NE:NME   6.05 ± 0.73   7.90 ± 0.96   5.34 ± 0.54   6.82 ± 0.83 12.85 ± 1.87   9.79 ± 1.44 
DA:DOPAC   6.56 ± 0.58   8.73 ± 1.40   0.93 ± 0.06   1.32 ± 0.14*   4.15 ± 0.59   4.28 ± 0.70 
DA:HVA   5.27 ± 0.39   5.28 ± 0.17   0.25 ± 0.25   0.35 ± 0.07   2.88 ± 0.45   2.61 ± 0.49 
5-HT:5-HIAA   1.69 ± 0.08   1.60 ± 0.08   0.63 ± 0.10   0.66 ± 0.11   3.01 ± 0.16   2.25 ± 0.21* 
Results are expressed as means; n=5-6.  Significant difference at *p<0.05 versus vehicle. 
 
Table 3.3 – MAO-A and -B activity in the brain 24 h after palmitic acid administration 
 Cortex Hippocampus Amygdala 
 Vehicle Palmitic Vehicle Palmitic Vehicle Palmitic 
MAO-A 4871 ± 112 5203 ± 223 11429 ± 455 11753 ± 547 9938 ± 481 10317 ± 354 
MAO-B 1572 ± 117   1889 ± 180  3540 ± 94 4602 ± 778 2728 ± 227  2662 ± 167 
Results are expressed as means; n=6. 
 
Table 3.4 – Brain expression of the UPR genes Xbp1, Edem1, Hsp90b1 and Atf4 24 hrs after palmitic 
acid administration 
 
Cortex Hippocampus Amygdala 
Vehicle Palmitic Vehicle Palmitic Vehicle Palmitic 
Xbp1   1.00 ± 0.08   0.95 ± 0.05   1.00 ± 0.06   1.12 ± 0.06   1.00 ± 0.64   0.97 ± 0.07 
Edem1   1.00 ± 0.07   0.95 ± 0.03   1.00 ± 0.10   1.12 ± 0.05   1.00 ± 0.07   0.97 ± 0.05 
Hsp90b1   1.00 ± 0.05   0.98 ± 0.04   1.00 ± 0.10   1.06 ± 0.05   1.00 ± 0.07   0.97 ± 0.05 
Atf4   1.00 ± 0.05   0.81 ± 0.03*   1.00 ± 0.10   1.04 ± 0.05   1.00 ± 0.07   0.89 ± 0.05 
Results are expressed as means; n=5-8. Significant difference at *p<0.05 versus vehicle. 
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